var title_f43_36_44608="Pituitary surgery PI";
var content_f43_36_44608=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F75464&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F75464&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 520px\">",
"   <div class=\"ttl\">",
"    Surgery to remove a pituitary tumor",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 500px; height: 470px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In this kind of surgery (called \"transsphenoidal surgery\"), the surgeon makes a small cut deep inside the nose. Then the surgeon inserts special tools into the \"sphenoid sinus,\" the hollow space below the pituitary gland. That way the surgeon has access to the pituitary gland and can remove the tumor. In some cases, surgeons do the surgery using a special tool called an \"endoscope,\" which is a long tube with a tiny camera and a light on the end.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_36_44608=[""].join("\n");
var outline_f43_36_44608=null;
var title_f43_36_44609="Positions of gaze";
var content_f43_36_44609=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F58849&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F58849&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Diagnostic positions of gaze",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 439px; height: 534px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The nine diagnostic positions of gaze, used for testing versions (saccades and pursuit). Pure elevation (supraduction) and depression (infraduction) of the eyes are predominantly functions of the superior and inferior rectus muscles, respectively, with some help from the oblique muscles. The eyes are rotated directly upward primarily by the superior rectus with some help from the inferior oblique; the eyes are rotated directly downward primarily by the inferior rectus with some help from the superior oblique.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Lavin, PJM. Eye movement disorders and diplopia. In: Neurology in Clinical Practice: Principles of Diagnosis and Management, 2nd ed, Bradley, WG (Ed), Butterworth-Heinemann, Boston 1996. p. 185. Copyright &copy; 1996 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_36_44609=[""].join("\n");
var outline_f43_36_44609=null;
var title_f43_36_44610="Disseminated superficial actinic porokeratosis";
var content_f43_36_44610=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F81874&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F81874&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Disseminated superficial actinic porokeratosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple well-defined, erythematous macules with a peripheral rim of scale are present on the leg of this patient with disseminated superficial actinic porokeratosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_36_44610=[""].join("\n");
var outline_f43_36_44610=null;
var title_f43_36_44611="Olsalazine: Patient drug information";
var content_f43_36_44611=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Olsalazine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/3/43059?source=see_link\">",
"     see \"Olsalazine: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?16/17/16659?source=see_link\">",
"     see \"Olsalazine: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F203247\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Dipentum&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F203248\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Dipentum&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10023624\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat ulcerative colitis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10023623\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702631",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to olsalazine, salicylates, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703761",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have had the varicella vaccine in the past 6 weeks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10023628\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697175",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have asthma, talk with your doctor. You may be more sensitive to this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698528",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking a blood thinner, have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10023629\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10023631\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699006",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain or bloody loose stools.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10023626\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695907",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug with food.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10023627\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10023632\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10023633\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10924 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.131.240.2-64F316EBC0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_36_44611=[""].join("\n");
var outline_f43_36_44611=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203247\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203248\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023624\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023623\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023628\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023629\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023631\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023626\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023627\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023632\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023633\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?42/3/43059?source=related_link\">",
"      Olsalazine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?16/17/16659?source=related_link\">",
"      Olsalazine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f43_36_44612="Icodextrin: Drug information";
var content_f43_36_44612=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Icodextrin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?22/42/23204?source=see_link\">",
"    see \"Icodextrin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F7869323\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F181621\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Extraneal",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F181636\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Adhesiolytic;",
"     </li>",
"     <li>",
"      Peritoneal Dialysate, Osmotic",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F181622\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      CAPD or APD (Extraneal&reg;):",
"     </b>",
"     Intraperitoneal: Given as a single daily exchange in CAPD or APD; dwell time of 8-16 hours is suggested",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Laparoscopic gynecologic surgery (Adept&reg;):",
"     </b>",
"     Intraperitoneal: Irrigate with at least 100 mL every 30 minutes during surgery; aspirate remaining fluid after surgery is completed, then instill 1 L into the cavity",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F181623\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F181602\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, intraperitoneal [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Extraneal: 7.5% (2 L, 2.5 L) [for peritoneal dialysis; contains sodium 132 mEq/L, calcium 3.5 mEq/L, magnesium 0.5 mEq/L, chloride 96 mEq/L, and lactate 40 mEq/L]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F181590\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F8104265\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM135933.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM135933.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F181604\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Intraperitoneal administration only; not for I.V. injection.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adept&reg;: Warm to body temperature prior to use",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Osmolarity: 278 mOsm/L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Extraneal&reg;: If using manual method, infuse into intraperitoneal cavity over 10-20 minutes. For increased comfort, dry heat (such as that derived from a heating pad) may be used to warm the solution in the over pouch to 37&deg;C (98.6&deg;F) prior to administration. Neither warm water nor the microwave should be used for warming.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Osmolarity: 282-286 mOsm/L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     pH: 5.0-6.0.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F181603\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adept&reg;: Reduction of postsurgical adhesions in gynecologic laparoscopic procedures",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Extraneal&reg;: Daily exchange for the long dwell (8- to 16-hour) during continuous ambulatory peritoneal dialysis (CAPD) or automated peritoneal dialysis (APD) for the management of end-stage renal disease (ESRD); improvement of long-dwell ultrafiltration and clearance of creatinine and urea nitrogen (compared to 4.25% dextrose) in patients with high/average or greater transport characteristics as measured by peritoneal equilibration test (PET)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F4432013\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       <b>",
"        Special care is warranted in patients with diabetes:",
"       </b>",
"       Due to potential interference by maltose, careful attention must be given to glucose monitoring; only glucose monitors and test strips which employ the glucose-specific method should be used. Inaccurate methods (glucose dehydrogenase pyrroloquinolinequinone [GDH-PQQ] or glucose-dye-oxidoreductase methods [GDO]) can result in falsely-elevated readings. Inaccurate readings may mask recognition of true hypoglycemia, or may prompt the administration of insulin, potentially leading to life-threatening consequences.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F181634\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      CAPD or APD (Extraneal&reg;):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Hypertension (13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Upper respiratory infection (15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Peritonitis (26% vs 25% in controls)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     5% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Edema (up to 6%), chest pain (5%), hypervolemia, hypotension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (9%), dizziness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatological: Rash (10%), pruritus, skin disorder",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hyperglycemia (5%), hyperphosphatemia, hypokalemia, hypoproteinemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain (8%), nausea (7%), dyspepsia (5%), diarrhea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Anemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, pain, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Cough increased (7%), dyspnea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Accidental injury (6%), flu syndrome (7%), infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;5%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Orthostatic hypotension, CHF",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Confusion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Exfoliative dermatitis, erythema multiforme, eczema, maculopapular rash, vesicobullous rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypercalcemia, hypochloremia, hypoglycemia, hyponatremia, alkaline phosphatase increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Abdominal enlargement, cramps",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: ALT increased, AST increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Infusion pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Cloudy effluent",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Laparoscopic surgery (Adept&reg;):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (35%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Dysmenorrhea (13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (6% to 17%), constipation (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Pyrexia (6%), insomnia (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Flatulence (8%), abdominal pain (7%), abdominal distention (6%), vomiting (6%), diarrhea (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Dysuria (7%), urinary tract infection (7%); labial, vulvar, or vaginal swelling (6%); vaginal bleeding (6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia (9%), back pain (8%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Nasopharyngitis (7%), cough (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Postmarketing and/or case reports: Sterile peritonitis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F181607\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to icodextrin, cornstarch, or any component of the formulation; patients with glycogen storage disease",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Adept&reg; is also contraindicated with infection of the abdominopelvic cavity; procedures with laparotomy incision; bowel resection or repair; appendectomy; maltose or isomaltose intolerance",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F181592\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Adept&reg;: Safety and efficacy have not been established for use in pregnancy, volumes left in peritoneal cavity &gt;1 L, hepatic or renal dysfunction, or with a breach in the vaginal epithelium. Effectiveness has not been established for long-term clinical outcomes following surgery (eg,  pregnancy, pain). Serious postoperative complications (dehiscence, cutaneous fistula formation) have been associated with laparotomy incision; anastomotic failure, ileus and peritonitis have been reported following bowel resection or repair, or appendectomy; use is contraindicated with these procedures. Postoperative leaking may occur through laparoscopic port site and may be associated with wound complications; meticulous closure of the fascia may help reduce complications. Use may be associated with vulvar swelling, most cases resolving within 1 week.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Extraneal&reg;: Use with caution with a history of abdominal surgery (within 30 days), abdominal fistulae, tumors, open wounds, hernia or other conditions which compromise the integrity of the abdominal wall, abdominal surface, or intra-abdominal cavity. Caution should be used in patients who are malnourished, have decreased respiratory function, decreased potassium, or increased calcium levels.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Safety and efficacy have not been established in children.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; I.V. administration: Do not administer intravenously.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Monitoring:",
"     <b>",
"      [U.S. Boxed Warning] Due to potential interference by maltose, careful attention must be given to glucose monitoring; only glucose monitors and test strips which employ the glucose-specific method should be used. Inaccurate methods (glucose dehydrogenase pyrroloquinolinequinone [GDH-PQQ] or glucose-dye-oxidoreductase methods [GDO]) can result in falsely-elevated readings.",
"     </b>",
"     Inaccurate readings may mask recognition of true hypoglycemia, or may prompt the administration of insulin, potentially leading to life-threatening consequences.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299507\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6220946\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F181598\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F181609\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Complete reproduction studies have not been conducted.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F181627\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F181610\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CAPD or APD: Monitor fluid intake; avoid over-/under hydration",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F181600\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CAPD: Serum electrolytes (chloride and sodium may be decreased); fluid balance",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038656\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Extraneal Dialysis Solution (AR, AU, BE, CH, CZ, DK, EE, FI, FR, HN, IE, IL, IT, NL, NO, NZ, PH, SE, SG, TH, TW)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F181591\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     When used for dialysis, icodextrin exerts osmotic pressure across small intercellular pores resulting in transcapillary ultrafiltration throughout the dwell while providing electrolytes and lactate for the maintenance of both the electrolyte and acid-base balance. When used for laparoscopic surgery, the colloidal osmotic action allows the fluid to be retained in the peritoneal cavity for 3-4 days, physically providing a temporary separation of peritoneal surfaces and minimizing adhesion formation.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F181606\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: 40% during 12-hour dwell (CAPD); slowly transferred into systemic circulation via peritoneal lymphatic drainage",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Primarily by alpha-amylase into maltose (DP2), maltotriose (DP3), maltotetraose (DP4), and other glucose polymers with a lower degree of polymerization",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, plasma: 13 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Renal (amount proportional to residual renal function); diasylate",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Frampton JE and Plosker GL, &ldquo;Icodextrin: a review of its use in peritoneal dialysis,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 2003, 63(19):2079-105.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/36/44612/abstract-text/12962523/pubmed\" id=\"12962523\" target=\"_blank\">",
"        12962523",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sutton C, Minelli L, Garcia E, et al, &ldquo;Use of Icodextrin 4% Solution in the Reduction of Adhesion Formation After Gynaecological Surgery,&rdquo;",
"      <i>",
"       Gynecol Surg",
"      </i>",
"      , 2005, 2(4): 287-296.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8769 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-61.234.146.186-ECB61E16A9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_36_44612=[""].join("\n");
var outline_f43_36_44612=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7869323\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181621\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181636\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181622\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181623\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181602\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181590\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8104265\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181604\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181603\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4432013\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181634\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181607\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181592\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299507\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6220946\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181598\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181609\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181627\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181610\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181600\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038656\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181591\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181606\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8769\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8769|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?22/42/23204?source=related_link\">",
"      Icodextrin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f43_36_44613="Electroanatomic map LV ischemia";
var content_f43_36_44613=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F81092&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F81092&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Endocardial electroanatomic map of myocardial ischemia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 283px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Shown are the right anterior oblique (A) and left anterior oblique (B) left ventricular (LV) local shortening (LS) map. Red represents regions with reduced LS (&lt;6 percent); yellow and green represents regions with mildly reduced LS (6 to 10 percent); blue and purple represent regions with LS &gt;10 percent. Panel C is the regional view of the same ventricle, presenting average LS values in 12 segments. Panel D is the right anterior oblique and panel E the left anterior oblique views of a unipolar voltage (UpV) of the same ventricle. Colors represent peak-to-peak amplitude of intracardiac electrogram, ranging from &le;5 mV (red) to &ge;16 mV (purple). Panel F is the regional view representing average regional UpV values of the same 12 segments. Ischemia produces a reduction in LS and decreased UpV.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted with permission from: Fuchs S, Hendel RC, Baim DS, et al. Am J Cardiol 2001; 87:874 with permission from Excerpta Medica Inc.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.elsevier.com/locate/jacc\">",
"      file://www.elsevier.com/locate/jacc",
"     </a>",
"     <br/>",
"     <a href=\" file://www.sciencedirect.com\">",
"      file://www.sciencedirect.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_36_44613=[""].join("\n");
var outline_f43_36_44613=null;
var title_f43_36_44614="Noninsulinoma pancreatogenous hypoglycemia syndrome";
var content_f43_36_44614=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Noninsulinoma pancreatogenous hypoglycemia syndrome",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/36/44614/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/36/44614/contributors\">",
"     F John Service, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/36/44614/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/36/44614/contributors\">",
"     Irl B Hirsch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/36/44614/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/36/44614/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?43/36/44614/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The noninsulinoma pancreatogenous hypoglycemia syndrome (NIPHS) identifies a group of hyperinsulinemic hypoglycemic patients with unique clinical, diagnostic, surgical, and pathologic features [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44614/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. These patients experience predominantly postprandial hypoglycemia and have nesidioblastosis with islet cell hypertrophy, findings different from those in patients with insulinomas.",
"   </p>",
"   <p>",
"    The clinical manifestations, diagnosis, pathological findings, and treatment of NIPHS will be reviewed here. Other causes of hypoglycemia and how to differentiate among these causes are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/39/44664?source=see_link\">",
"     \"Hypoglycemia in adults: Clinical manifestations, definition, and causes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/39/24184?source=see_link\">",
"     \"Hypoglycemia in adults without diabetes mellitus: Diagnostic approach\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Noninsulinoma pancreatogenous hypoglycemia is a syndrome characterized by endogenous hyperinsulinemic hypoglycemia that is not caused by an insulinoma. Pancreatic specimens from such patients show beta cell hypertrophy, islets with enlarged and hyperchromatic nuclei, and increased periductular islets [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44614/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. These histologic findings are characteristic of nesidioblastosis, a term that refers to neoformation of islets of Langerhans from pancreatic duct epithelium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44614/abstract/4\">",
"     4",
"    </a>",
"    ]. The pathologic findings are similar to those seen in neonates and infants with persistent hyperinsulinemic hypoglycemia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/49/3866?source=see_link&amp;anchor=H10#H10\">",
"     \"Pathogenesis, clinical features, and diagnosis of persistent hyperinsulinemic hypoglycemia of infancy\", section on 'Pathology of the beta cell'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is usually not difficult to distinguish insulinoma from noninsulinoma pancreatogenous hypoglycemia syndrome (NIPHS) considering the timing of symptoms, gender preference (male predominance), and radiologic localization study results. Pathologic findings can confirm the presence of nesidioblastosis, which is the typical finding in patients with NIPHS and is only rarely described as a concomitant finding in patients with insulinoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44614/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;The predominant clinical feature of noninsulinoma pancreatogenous hypoglycemia syndrome (NIPHS) is postprandial hypoglycemia. In a series of 18 patients from the Mayo Clinic, age range 16 to 78 years old with male predominance (70 percent), symptoms occurred postprandially, two to four hours after meals, and only rarely while fasting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44614/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. All patients had neuroglycopenic symptoms, and several lost consciousness or had generalized seizures. In smaller series and case reports, a similar preponderance of postprandial hypoglycemia and male predominance was noted [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44614/abstract/7-13\">",
"     7-13",
"    </a>",
"    ]. However, fasting hypoglycemia has also been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44614/abstract/13-15\">",
"     13-15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, most patients with insulinomas have fasting hypoglycemia. Though they may occasionally also have postprandial symptoms, the occurrence of symptoms solely postprandially is rare (approximately 5 percent of patients). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/30/12777?source=see_link&amp;anchor=H2#H2\">",
"     \"Insulinoma\", section on 'Clinical features'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Biochemical findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;During episodes of hypoglycemia, patients with NIPHS have biochemical findings similar to those of insulinoma, including elevated plasma insulin, C-peptide, and proinsulin concentrations, low plasma beta-hydroxybutyrate, and a negative",
"    <span class=\"nowrap\">",
"     sulfonylurea/meglitinide",
"    </span>",
"    screen (",
"    <a class=\"graphic graphic_table graphicRef56314 \" href=\"mobipreview.htm?12/24/12685\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/39/24184?source=see_link&amp;anchor=H6#H6\">",
"     \"Hypoglycemia in adults without diabetes mellitus: Diagnostic approach\", section on 'Laboratory testing'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A negative 72-hour fast in a patient with insulinoma is uncommon; among 178 patients with insulinomas who underwent a 72-hour fast at the Mayo Clinic, all except one had hypoglycemia during the fast. In contrast, a 72-hour fast does not typically provoke hypoglycemia in patients with NIPHS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44614/abstract/1\">",
"     1",
"    </a>",
"    ]. In some reports, however, the response to a 72-hour fast was variable, despite histological confirmation of nesidioblastosis with islet hypertrophy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44614/abstract/8,14,16,17\">",
"     8,14,16,17",
"    </a>",
"    ]. Thus, a negative 72-hour fast is suggestive of noninsulinoma pancreatogenous hypoglycemia; a positive test is more consistent with insulinoma. However, the hypoglycemic response to a 72-hour fast cannot definitively distinguish NIPHS from insulinoma. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/39/24184?source=see_link&amp;anchor=H9#H9\">",
"     \"Hypoglycemia in adults without diabetes mellitus: Diagnostic approach\", section on '72-hour fast'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Localization studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiological localization studies are negative in patients with NIPHS. In the Mayo series, as an example, all radiologic studies (transabdominal ultrasonography, triple phase computed tomography, celiac axis angiography, and intraoperative ultrasonography) were negative for insulinoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44614/abstract/1\">",
"     1",
"    </a>",
"    ]. The sensitivity of each of these preoperative studies is only about 50 to 60 percent, but their combined sensitivity is significantly higher.",
"   </p>",
"   <p>",
"    In patients with complex cases of endogenous hyperinsulinemic hypoglycemia and negative radiologic localization studies, a selective arterial calcium stimulation test (SACST) with hepatic venous sampling can be performed to distinguish between a focal abnormality (insulinoma) and a diffuse process (islet cell",
"    <span class=\"nowrap\">",
"     hypertrophy/nesidioblastosis).",
"    </span>",
"   </p>",
"   <p>",
"    A SACST involves injections of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/11/18616?source=see_link\">",
"     calcium gluconate",
"    </a>",
"    , an insulin secretagogue, into arteries supplying the pancreas with subsequent sampling of the hepatic venous effluent for insulin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44614/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. A positive result is defined as a doubling or tripling of the basal hepatic venous serum insulin concentration. The increase in insulin occurs in samples from the artery supplying the region with hyperfunctioning islets, either an insulinoma or islet hypertrophy, which facilitates operative localization.",
"   </p>",
"   <p>",
"    In patients with noninsulinoma pancreatogenous hypoglycemia syndrome, positive responses are usually observed after injection of multiple arteries, in contrast to insulinoma where the response is positive in one artery alone unless the tumor resides in an area fed by two arteries, or the patient has multiple insulinomas scattered throughout the pancreas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44614/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/39/24184?source=see_link&amp;anchor=H24#H24\">",
"     \"Hypoglycemia in adults without diabetes mellitus: Diagnostic approach\", section on 'Arterial calcium stimulation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/30/12777?source=see_link&amp;anchor=H13#H13\">",
"     \"Insulinoma\", section on 'Tumor localization'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/57/18330?source=see_link\">",
"     \"Classification, epidemiology, clinical presentation, localization, and staging of pancreatic neuroendocrine tumors (islet-cell tumors)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Pathologic findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Histopathology descriptions of excised pancreatic tissue include islet cell hypertrophy with enlarged and hyperchromatic nuclei, sometimes islet cell hyperplasia, and increased periductular islets [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44614/abstract/1,3,8\">",
"     1,3,8",
"    </a>",
"    ]. Islet-like cells budding off exocrine ducts have been noted and were most evident on immunohistochemical staining for chromogranin A (",
"    <a class=\"graphic graphic_picture graphicRef51119 \" href=\"mobipreview.htm?23/39/24182\">",
"     picture 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44614/abstract/1\">",
"     1",
"    </a>",
"    ]. The hypertrophic islet cells also stained positively for insulin, glucagon, somatostatin, and pancreatic polypeptide [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44614/abstract/1,9\">",
"     1,9",
"    </a>",
"    ]. The distribution of the hormones within the islets was normal, with between 60 to 80 percent of the islet cells staining for insulin. Many of the cells budding off ducts also contained insulin.",
"   </p>",
"   <p>",
"    This constellation of pathologic changes is referred to as nesidioblastosis, a form of primary islet cell hypertrophy and neodifferentiation of islet of Langerhans cells from pancreatic duct epithelium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44614/abstract/3\">",
"     3",
"    </a>",
"    ]. Nesidioblastosis has been associated with persistent hyperinsulinemic hypoglycemia in infants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44614/abstract/4,20,21\">",
"     4,20,21",
"    </a>",
"    ] and less often in adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44614/abstract/3,17,22-27\">",
"     3,17,22-27",
"    </a>",
"    ]. These pathologic findings have also been described in nontumor pancreatic tissue of patients with insulinomas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44614/abstract/5,6\">",
"     5,6",
"    </a>",
"    ], in patients previously treated with insulin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44614/abstract/24,28\">",
"     24,28",
"    </a>",
"    ] or a sulfonylurea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44614/abstract/29\">",
"     29",
"    </a>",
"    ], and in patients with other islet cell tumors such as gastrinomas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44614/abstract/30\">",
"     30",
"    </a>",
"    ] or multiple endocrine neoplasia type 1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44614/abstract/31\">",
"     31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/49/3866?source=see_link\">",
"     \"Pathogenesis, clinical features, and diagnosis of persistent hyperinsulinemic hypoglycemia of infancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/39/24184?source=see_link&amp;anchor=H18#H18\">",
"     \"Hypoglycemia in adults without diabetes mellitus: Diagnostic approach\", section on 'Determining the cause of hypoglycemia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Whether these pathologic findings directly correlate with the clinical features of the syndrome of hyperinsulinemic hypoglycemia in adults is controversial. Subtle histologic changes characteristic of nesidioblastosis were found in 36 percent of patients in an autopsy series of 207 patients with no history of hypoglycemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44614/abstract/32\">",
"     32",
"    </a>",
"    ]. Some have proposed that the morphologic features of nesidioblastosis may be a variant of normal rather than the anatomic basis for hypoglycemia in adults with hyperinsulinism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44614/abstract/32,33\">",
"     32,33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, in an analysis of pancreatic tissue from 36 cases (27 post gastric bypass) of nesidioblastosis, increased insulin-like growth factor 2, insulin-like growth factor 1 receptor alpha, and transforming growth factor receptor beta 3 expression were noted in the islets of patients compared with controls who had benign exocrine pancreatic tumors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44614/abstract/34\">",
"     34",
"    </a>",
"    ]. These findings suggest a role for growth factors in the pathogenesis of nesidioblastosis in adults.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     NESIDIOBLASTOSIS AFTER ROUX-EN-Y GASTRIC BYPASS SURGERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although endogenous hyperinsulinemic hypoglycemia is rare, there have been several reports of it occurring after Roux-en-y gastric bypass (RYGB) surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44614/abstract/35-38\">",
"     35-38",
"    </a>",
"    ]. In the initial series, six patients developed symptomatic postprandial hypoglycemia (symptoms of confusion, tunnel vision, and loss of consciousness occurring one to three hours after eating) six months to eight years following RYGB [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44614/abstract/35\">",
"     35",
"    </a>",
"    ]. Five of these patients had evidence of islet cell hyperplasia (nesidioblastosis) and one had both nesidioblastosis and evidence of a multifocal insulinoma.",
"   </p>",
"   <p>",
"    In a subsequent report, 36 patients who underwent partial pancreatectomy for nesidioblastosis at Mayo Clinic between 1994 and 2007 were evaluated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44614/abstract/34\">",
"     34",
"    </a>",
"    ]. Twenty-seven of the patients had previously undergone RYGB. The time from RYGB to pancreatic resection was on average 54 months. In contrast to patients with NIPHS, there was a female predominance (92 percent). Patients with severe postprandial hypoglycemia and pancreatic islet hyperplasia after RYGB have also been reported from other institutions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44614/abstract/36-38\">",
"     36-38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nesidioblastosis following RYGB appears to be a disease different from the noninsulinoma pancreatogenous hypoglycemia syndrome. Several hypotheses have been proposed for the etiology of islet cell hyperplasia following Roux-en-y bypass surgery: hormonal changes (possibly involving insulin-stimulating GLP-1 or decreased ghrelin), unidentified factors from the proximal intestine, or disruption in the presurgery homeostasis of insulin resistance and hyperinsulinemia with rapid weight loss [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44614/abstract/35,36,39-42\">",
"     35,36,39-42",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/58/41898?source=see_link&amp;anchor=H37#H37\">",
"     \"Complications of bariatric surgery\", section on 'Postoperative hypoglycemia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are limited data evaluating the efficacy of surgical therapy for NIPHS and post gastric bypass nesidioblastosis. In case series and reports, partial or subtotal pancreatectomy successfully relieved hypoglycemic symptoms in the majority of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44614/abstract/1,2,13,26,27,35,36,38\">",
"     1,2,13,26,27,35,36,38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The degree of surgery is determined by the results of the selective arterial calcium stimulation test. The pancreas to the left of the superior mesenteric vein is resected when the selective arterial calcium stimulation test is positive only after splenic artery injection, and the resection is extended to the right of the superior mesenteric vein when the test is positive after injection of an additional artery. The pancreas can be debulked in a gradient-guided fashion, even in patients whose disease appears to involve the whole pancreas.",
"   </p>",
"   <p>",
"    Recurrent hypoglycemia after partial pancreatectomy has been observed. In the series of six patients who had symptoms following bypass surgery, three patients had total symptom amelioration with partial pancreatectomy, two had marked symptom improvement, and one responded less successfully but had had more limited surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44614/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;In case reports,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/38/13924?source=see_link\">",
"     diazoxide",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44197?source=see_link\">",
"     acarbose",
"    </a>",
"    have reportedly improved hypoglycemic symptoms in patients with post-gastric bypass hypoglycemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44614/abstract/37,43,44\">",
"     37,43,44",
"    </a>",
"    ]. However, the evaluation of these patients did not always include careful documentation of postprandial hyperinsulinemic hypoglycemia and, therefore, the diagnosis of hypoglycemia due to nesidioblastosis is uncertain. Some of these patients may have had dumping syndrome or another cause of post-bypass symptoms. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/58/41898?source=see_link&amp;anchor=H37#H37\">",
"     \"Complications of bariatric surgery\", section on 'Postoperative hypoglycemia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/30/12777?source=see_link&amp;anchor=H25#H25\">",
"     \"Insulinoma\", section on 'Medical therapy to control symptomatic hypoglycemia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Similarly, nutritional modification, particularly reduction of carbohydrate intake, has been reported to reduce postprandial glycemic excursions and mild symptoms of hypoglycemia in some patients with post-bypass postprandial hypoglycemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44614/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These approaches are not recommended for patients with severe postprandial hypoglycemia due to nesidioblastosis. In such patients, surgical therapy is typically required.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The diagnosis of noninsulinoma pancreatogenous hypoglycemia syndrome (NIPHS) should be suspected in a patient with postprandial endogenous hyperinsulinemic hypoglycemia, negative radiological localizing studies, and a positive selective arterial calcium stimulation test. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical features'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/39/24184?source=see_link\">",
"       \"Hypoglycemia in adults without diabetes mellitus: Diagnostic approach\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      It is usually not difficult to differentiate NIPHS from insulinoma based upon clinical features alone. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical features'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/30/12777?source=see_link\">",
"       \"Insulinoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In patients with the clinical features described above, the diagnosis of NIPHS may be confirmed when pancreatic specimens from such patients show beta cell hypertrophy, islets with enlarged and hyperchromatic nuclei, and increased periductular islets by the presence of histomorphometric findings. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Pathologic findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Amelioration of symptoms usually occurs with partial or subtotal pancreatectomy. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44614/abstract/1\">",
"      Service FJ, Natt N, Thompson GB, et al. Noninsulinoma pancreatogenous hypoglycemia: a novel syndrome of hyperinsulinemic hypoglycemia in adults independent of mutations in Kir6.2 and SUR1 genes. J Clin Endocrinol Metab 1999; 84:1582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44614/abstract/2\">",
"      Thompson GB, Service FJ, Andrews JC, et al. Noninsulinoma pancreatogenous hypoglycemia syndrome: an update in 10 surgically treated patients. Surgery 2000; 128:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44614/abstract/3\">",
"      Anlauf M, Wieben D, Perren A, et al. Persistent hyperinsulinemic hypoglycemia in 15 adults with diffuse nesidioblastosis: diagnostic criteria, incidence, and characterization of beta-cell changes. Am J Surg Pathol 2005; 29:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44614/abstract/4\">",
"      Laidlaw, GF. Nesidioblastoma, the islet tumor of the pancreas. Am J Pathol 1938; 2:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44614/abstract/5\">",
"      Campbell IL, Harrison LC, Ley CJ, et al. Nesidioblastosis and multifocal pancreatic islet cell hyperplasia in an adult. Clinicopathologic features and in vitro pancreatic studies. Am J Clin Pathol 1985; 84:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44614/abstract/6\">",
"      Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 1-1983. A 37-year-old schizophrenic woman with hypoglycemic episode. N Engl J Med 1983; 308:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44614/abstract/7\">",
"      Kenney B, Tormey CA, Qin L, et al. Adult nesidioblastosis. Clinicopathologic correlation between pre-operative selective arterial calcium stimulation studies and post-operative pathologic findings. JOP 2008; 9:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44614/abstract/8\">",
"      Won JG, Tseng HS, Yang AH, et al. Clinical features and morphological characterization of 10 patients with noninsulinoma pancreatogenous hypoglycaemia syndrome (NIPHS). Clin Endocrinol (Oxf) 2006; 65:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44614/abstract/9\">",
"      Sahloul R, Yaqub N, Driscoll HK, et al. Noninsulinoma pancreatogenous hypoglycemia syndrome: quantitative and immunohistochemical analyses of islet cells for insulin, glucagon, somatostatin, and pancreatic and duodenal homeobox protein. Endocr Pract 2007; 13:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44614/abstract/10\">",
"      Hong R, Choi DY, Lim SC. Hyperinsulinemic hypoglycemia due to diffuse nesidioblastosis in adults: a case report. World J Gastroenterol 2008; 14:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44614/abstract/11\">",
"      Tsujino M, Sugiyama T, Nishida K, et al. Noninsulinoma pancreatogenous hypoglycemia syndrome: a rare case of adult-onset nesidioblastosis. Intern Med 2005; 44:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44614/abstract/12\">",
"      Kim HK, Shong YK, Han DJ, et al. Nesidioblastosis in an adult with hyperinsulinemic hypoglycemia. Endocr J 1996; 43:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44614/abstract/13\">",
"      Starke A, Saddig C, Kirch B, et al. Islet hyperplasia in adults: challenge to preoperatively diagnose non-insulinoma pancreatogenic hypoglycemia syndrome. World J Surg 2006; 30:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44614/abstract/14\">",
"      Nathan DM, Axelrod L, Proppe KH, et al. Nesidioblastosis associated with insulin-mediated hypoglycemia in an adult. Diabetes Care 1981; 4:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44614/abstract/15\">",
"      McHenry C, Newell K, Chejfec G, et al. Adult nesidioblastosis. An unusual cause of fasting hypoglycemia. Am Surg 1989; 55:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44614/abstract/16\">",
"      Albers N, L&ouml;hr M, Bogner U, et al. Nesidioblastosis of the pancreas in an adult with persistent hyperinsulinemic hypoglycemia. Am J Clin Pathol 1989; 91:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44614/abstract/17\">",
"      Walmsley D, Matheson NA, Ewen S, et al. Nesidioblastosis in an elderly patient. Diabet Med 1995; 12:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44614/abstract/18\">",
"      Doppman JL, Chang R, Fraker DL, et al. Localization of insulinomas to regions of the pancreas by intra-arterial stimulation with calcium. Ann Intern Med 1995; 123:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44614/abstract/19\">",
"      O'Shea D, Rohrer-Theurs AW, Lynn JA, et al. Localization of insulinomas by selective intraarterial calcium injection. J Clin Endocrinol Metab 1996; 81:1623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44614/abstract/20\">",
"      de Lonlay P, Fournet JC, Rahier J, et al. Somatic deletion of the imprinted 11p15 region in sporadic persistent hyperinsulinemic hypoglycemia of infancy is specific of focal adenomatous hyperplasia and endorses partial pancreatectomy. J Clin Invest 1997; 100:802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44614/abstract/21\">",
"      de Lonlay-Debeney P, Poggi-Travert F, Fournet JC, et al. Clinical features of 52 neonates with hyperinsulinism. N Engl J Med 1999; 340:1169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44614/abstract/22\">",
"      Tibaldi JM, Lorber D, Lomasky S, et al. Postprandial hypoglycemia in islet beta cell hyperplasia with adenomatosis of the pancreas. J Surg Oncol 1992; 50:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44614/abstract/23\">",
"      Burman WJ, McDermott MT, Bornemann M. Familial hyperinsulinism presenting in adults. Arch Intern Med 1992; 152:2125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44614/abstract/24\">",
"      Bell DS, Grizzle WE, Dunlap NE. Nesidioblastosis causing reversal of insulin-dependent diabetes and development of hyperinsulinemic hypoglycemia. Diabetes Care 1995; 18:1379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44614/abstract/25\">",
"      Carlson T, Eckhauser ML, DeBaz B, et al. Nesidioblastosis in an adult: an illustrative case and collective review. Am J Gastroenterol 1987; 82:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44614/abstract/26\">",
"      Raffel A, Krausch M M, Anlauf M, et al. Diffuse nesidioblastosis as a cause of hyperinsulinemic hypoglycemia in adults: a diagnostic and therapeutic challenge. Surgery 2007; 141:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44614/abstract/27\">",
"      Toyomasu Y, Fukuchi M, Yoshida T, et al. Treatment of hyperinsulinemic hypoglycemia due to diffuse nesidioblastosis in adults: a case report. Am Surg 2009; 75:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44614/abstract/28\">",
"      Sandler R, Horwitz DL, Rubenstein AH, Kuzuya H. Hypoglycemia and endogenous hyperinsulinism complicating diabetes mellitus. Application of the C-peptide assay to diagnosis and therapy. Am J Med 1975; 59:730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44614/abstract/29\">",
"      Rayman G, Santo M, Salomon F, et al. Hyperinsulinaemic hypoglycaemia due to chlorpropamide-induced nesidioblastosis. J Clin Pathol 1984; 37:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44614/abstract/30\">",
"      Farley DR, van Heerden JA, Myers JL. Adult pancreatic nesidioblastosis. Unusual presentations of a rare entity. Arch Surg 1994; 129:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44614/abstract/31\">",
"      Thompson NW, Lloyd RV, Nishiyama RH, et al. MEN I pancreas: a histological and immunohistochemical study. World J Surg 1984; 8:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44614/abstract/32\">",
"      Karnauchow PN. Nesidioblastosis in adults without insular hyperfunction. Am J Clin Pathol 1982; 78:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44614/abstract/33\">",
"      Goudswaard WB, Houthoff HJ, Koudstaal J, Zwierstra RP. Nesidioblastosis and endocrine hyperplasia of the pancreas: a secondary phenomenon. Hum Pathol 1986; 17:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44614/abstract/34\">",
"      Rumilla KM, Erickson LA, Service FJ, et al. Hyperinsulinemic hypoglycemia with nesidioblastosis: histologic features and growth factor expression. Mod Pathol 2009; 22:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44614/abstract/35\">",
"      Service GJ, Thompson GB, Service FJ, et al. Hyperinsulinemic hypoglycemia with nesidioblastosis after gastric-bypass surgery. N Engl J Med 2005; 353:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44614/abstract/36\">",
"      Patti ME, McMahon G, Mun EC, et al. Severe hypoglycaemia post-gastric bypass requiring partial pancreatectomy: evidence for inappropriate insulin secretion and pancreatic islet hyperplasia. Diabetologia 2005; 48:2236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44614/abstract/37\">",
"      Goldfine, AB, Mun, E, Patti, ME. Hyperinsulinemic hypoglycemia following gastric bypass surgery for obesity. Current Opinion in Endocrinology, DIabetes and Obesity 2006; 13:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44614/abstract/38\">",
"      Clancy TE, Moore FD Jr, Zinner MJ. Post-gastric bypass hyperinsulinism with nesidioblastosis: subtotal or total pancreatectomy may be needed to prevent recurrent hypoglycemia. J Gastrointest Surg 2006; 10:1116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44614/abstract/39\">",
"      Cummings DE. Gastric bypass and nesidioblastosis--too much of a good thing for islets? N Engl J Med 2005; 353:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44614/abstract/40\">",
"      Kaiser AM. Hyperinsulinemic hypoglycemia with nesidioblastosis after gastric-bypass surgery. N Engl J Med 2005; 353:2192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44614/abstract/41\">",
"      Goldfine AB, Mun EC, Devine E, et al. Patients with neuroglycopenia after gastric bypass surgery have exaggerated incretin and insulin secretory responses to a mixed meal. J Clin Endocrinol Metab 2007; 92:4678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44614/abstract/42\">",
"      Vella A, Service FJ. Incretin hypersecretion in post-gastric bypass hypoglycemia--primary problem or red herring? J Clin Endocrinol Metab 2007; 92:4563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44614/abstract/43\">",
"      Spanakis E, Gragnoli C. Successful medical management of status post-Roux-en-Y-gastric-bypass hyperinsulinemic hypoglycemia. Obes Surg 2009; 19:1333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44614/abstract/44\">",
"      Moreira RO, Moreira RB, Machado NA, et al. Post-prandial hypoglycemia after bariatric surgery: pharmacological treatment with verapamil and acarbose. Obes Surg 2008; 18:1618.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1782 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-219.243.220.100-85C35604D9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_36_44614=[""].join("\n");
var outline_f43_36_44614=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Biochemical findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Localization studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Pathologic findings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      NESIDIOBLASTOSIS AFTER ROUX-EN-Y GASTRIC BYPASS SURGERY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/1782\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/1782|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?23/39/24182\" title=\"picture 1\">",
"      Nesidioblastosis Light",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/1782|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?12/24/12685\" title=\"table 1\">",
"      Interpretation 72 hour fast",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/57/18330?source=related_link\">",
"      Classification, epidemiology, clinical presentation, localization, and staging of pancreatic neuroendocrine tumors (islet-cell tumors)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/58/41898?source=related_link\">",
"      Complications of bariatric surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/39/24184?source=related_link\">",
"      Hypoglycemia in adults without diabetes mellitus: Diagnostic approach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/39/44664?source=related_link\">",
"      Hypoglycemia in adults: Clinical manifestations, definition, and causes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/30/12777?source=related_link\">",
"      Insulinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/49/3866?source=related_link\">",
"      Pathogenesis, clinical features, and diagnosis of persistent hyperinsulinemic hypoglycemia of infancy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f43_36_44615="Ankyloglossia (tongue-tie) in infants and children";
var content_f43_36_44615=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Ankyloglossia (tongue-tie) in infants and children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/36/44615/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/36/44615/contributors\">",
"     Glenn C Isaacson, MD, FAAP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/36/44615/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/36/44615/contributors\">",
"     Ellen M Friedman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/36/44615/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/36/44615/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?43/36/44615/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ankyloglossia, or tongue-tie, is a congenital anomaly in which a short, lingual frenulum or a highly attached genioglossus muscle restricts tongue movement (ie, restrictive lingual frenulum) (",
"    <a class=\"graphic graphic_picture graphicRef74275 graphicRef60685 \" href=\"mobipreview.htm?18/12/18631\">",
"     picture 1A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44615/abstract/1\">",
"     1",
"    </a>",
"    ]. The definition of ankyloglossia is not standardized, and there is wide variation of opinion regarding its clinical significance and optimal management [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44615/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ankyloglossia will be discussed below. Other congenital anomalies of the tongue are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/59/1977?source=see_link\">",
"     \"Congenital anomalies of the jaw, mouth, oral cavity, and pharynx\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Published information about ankyloglossia largely consists of case series and observational studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44615/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Depending upon the study population and criteria used to define ankyloglossia, the reported prevalence varies from &lt;1 percent to 10.7 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44615/abstract/1,4,6-14\">",
"     1,4,6-14",
"    </a>",
"    ]. The variation in reported incidence may be attributed in part to the lack of a uniform definition and objective grading system for tongue-tie [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44615/abstract/15\">",
"     15",
"    </a>",
"    ]. Several authors have tried to develop standardized measurement techniques and norms (",
"    <a class=\"graphic graphic_figure graphicRef72528 \" href=\"mobipreview.htm?9/25/9616\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef70911 \" href=\"mobipreview.htm?21/1/21535\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44615/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. Most series identify an increased frequency in boys with a male-to-female ratio of 1.5-2.6 to 1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44615/abstract/4\">",
"     4",
"    </a>",
"    ]. While most cases of ankyloglossia are sporadic, mutations in the T-box transcription factor TBX22 may lead to heritable (X-linked) ankyloglossia with or without cleft lip, cleft palate, or hypodontia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44615/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical features of ankyloglossia may include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44615/abstract/1,15,18\">",
"     1,15,18",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Abnormally short frenulum, inserting at or near the tip of the tongue (",
"      <a class=\"graphic graphic_picture graphicRef74275 graphicRef60685 \" href=\"mobipreview.htm?18/12/18631\">",
"       picture 1A-B",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Difficulty lifting the tongue to the upper dental alveolus (",
"      <a class=\"graphic graphic_picture graphicRef50442 \" href=\"mobipreview.htm?0/55/882\">",
"       picture 2",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Inability to protrude the tongue more than 1 to 2 mm past the lower central incisors (",
"      <a class=\"graphic graphic_picture graphicRef61044 \" href=\"mobipreview.htm?14/53/15184\">",
"       picture 3",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Impaired side-to-side movement of the tongue",
"     </li>",
"     <li>",
"      Notched or heart shape of the tongue when it is protruded (",
"      <a class=\"graphic graphic_figure graphicRef67272 \" href=\"mobipreview.htm?5/57/6032\">",
"       figure 3",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The natural history is unknown [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44615/abstract/15\">",
"     15",
"    </a>",
"    ]. Some postulate that progressive stretching and use of the frenulum leads to spontaneous elongation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44615/abstract/1,19,20\">",
"     1,19,20",
"    </a>",
"    ], but this has not been substantiated in prospective studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44615/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15215595\">",
"    <span class=\"h2\">",
"     &ldquo;Posterior&rdquo; ankyloglossia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Functional ankyloglossia without anterior tethering of the tongue has been described by some as posterior ankyloglossia.",
"    <strong>",
"    </strong>",
"    This is a misnomer, since the putative site of restriction is the anterior portion of the genioglossus muscle, not the (posterior) base of tongue [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44615/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     POTENTIAL SEQUELAE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Impaired tongue mobility may be associated with breastfeeding difficulty (eg, poor latch, maternal nipple pain), speech (articulation) difficulty, mechanical problems, and social embarrassment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44615/abstract/15,22-24\">",
"     15,22-24",
"    </a>",
"    ]. Poor latch with resultant low milk transfer can lead to failure to thrive in the exclusively breastfed infant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44615/abstract/11,25\">",
"     11,25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The extent to which tongue-tie results in clinically significant symptoms is controversial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44615/abstract/15\">",
"     15",
"    </a>",
"    ]. There is little high-quality evidence regarding this issue, with published information consisting largely of case series and observational studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44615/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Opinions among pediatricians, speech pathologists, lactation consultants, and otolaryngologists vary widely [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44615/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Breastfeeding problems",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of infants with tongue-tie are able to breastfeed without difficulty (",
"    <a class=\"graphic graphic_figure graphicRef63201 \" href=\"mobipreview.htm?8/47/8959\">",
"     figure 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44615/abstract/7\">",
"     7",
"    </a>",
"    ]. However, breastfeeding problems (eg, poor latch, maternal nipple pain) are reported more frequently among infants with ankyloglossia than without ankyloglossia (25 versus 3 percent in one series) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44615/abstract/7,11\">",
"     7,11",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Breastfeeding issues'",
"    </a>",
"    below.) Frenotomy may be necessary to prolong the duration of breastfeeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44615/abstract/9,10,26,27\">",
"     9,10,26,27",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Frenotomy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Infants who have problems with breastfeeding after lactation is established should be examined for ankyloglossia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44615/abstract/4\">",
"     4",
"    </a>",
"    ]. Consultation with a lactation consultant to exclude other causes of breastfeeding difficulty is a helpful initial step in the evaluation of an infant with ankyloglossia and difficulty breastfeeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44615/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/39/42616?source=see_link\">",
"     \"Breastfeeding: Parental education and support\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/15/17658?source=see_link\">",
"     \"Common problems of breastfeeding and weaning\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are no studies examining the effect of ankyloglossia on bottle feeding, most likely because it is rarely an issue due to the differences in mechanics between breast and bottle feeding. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/4/21576?source=see_link\">",
"     \"Sucking and swallowing disorders in the newborn\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Articulation problems",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effect of ankyloglossia on speech is not clearly defined [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44615/abstract/2,15\">",
"     2,15",
"    </a>",
"    ]. Ankyloglossia may cause articulation problems in some children, but does not prevent vocalization or delay the onset of speech [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44615/abstract/15,22,28\">",
"     15,22,28",
"    </a>",
"    ]. Frenula that extend to the tip of the tongue and prevent the tongue from reaching the upper dental alveolus are most likely to be of clinical significance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44615/abstract/18\">",
"     18",
"    </a>",
"    ]. Speech sounds that may be affected include sibilants and lingual sounds (eg, \"t,\" \"d,\" \"z,\" \"s,\" \"th,\" \"n,\" \"l\") [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44615/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Articulation problems may not be recognized or reported by the parents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44615/abstract/6\">",
"     6",
"    </a>",
"    ]. Formal speech evaluation should be obtained in children who have ankyloglossia and difficulty pronouncing sibilants and lingual sounds [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44615/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/46/26343?source=see_link\">",
"     \"Evaluation and treatment of speech and language disorders in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Mechanical problems",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mechanical problems related to ankyloglossia may include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44615/abstract/15,19,22\">",
"     15,19,22",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Difficulty with oral hygiene (ie, licking the lips or sweeping food debris from the teeth) that may result in periodontal disease (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/45/32471?source=see_link&amp;anchor=H4#H4\">",
"       \"Overview of gingivitis and periodontitis in children and adolescents\", section on 'Gingivitis'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Local discomfort",
"     </li>",
"     <li>",
"      Diastasis between the lower central incisors",
"     </li>",
"     <li>",
"      Difficulty licking an ice-cream cone, playing a wind instrument, or kissing",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Consultation with a lactation specialist",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    speech therapy may help the child to compensate for problems related to ankyloglossia, thereby avoiding surgery. Definitive treatment requires surgery.",
"   </p>",
"   <p>",
"    There is a lack of consensus among clinicians regarding indications and optimal timing of surgical division for ankyloglossia. Decisions regarding surgery are usually made by the clinician(s) and the child's parents, after discussion of the potential benefits and risks of the procedure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44615/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Potential indications for surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of surgery is to increase the mobility of the tongue, not to improve its contour. Even after surgery, the tip of the tongue may retain a heart shape.",
"   </p>",
"   <p>",
"    Indications for surgery may include breastfeeding difficulty, articulation problems, psychologic problems, and periodontal disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44615/abstract/1,15,28\">",
"     1,15,28",
"    </a>",
"    ]. Delayed acquisition of speech is not an indication for surgical release of tongue tie; children with ankyloglossia are expected to acquire speech and language at the normal rate.",
"   </p>",
"   <p>",
"    The optimal timing of surgery is controversial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44615/abstract/2,3,15\">",
"     2,3,15",
"    </a>",
"    ]. Dividing a tongue-tie in infancy has some appeal, since it usually can be accomplished without general anesthesia. Most authors agree that this should not be done for purely cosmetic reasons or fear of future language delay. Some advocate waiting until the child is at least four years old because of the chance that the tongue may spontaneously elongate as it is used [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44615/abstract/1,19,20\">",
"     1,19,20",
"    </a>",
"    ], whereas others advocate surgery before the development of feeding, speech, or other problems [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44615/abstract/15,30\">",
"     15,30",
"    </a>",
"    ]. Cooperative young adults may undergo division of the frenulum under local anesthesia in the office if a tongue-tie interferes with oral hygiene or kissing. Given the lack of consensus, decisions regarding surgery should be made on a case-by-case basis with involvement of the parents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Breastfeeding issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment alternatives for infants with ankyloglossia and difficulty breastfeeding include support from a lactation consultant and surgical division. These alternatives were compared in a prospective trial in which 57 infants with ankyloglossia and feeding problems were randomly assigned to 48 hours of intensive support from a lactation consultant (controls) or immediate division (frenotomy, frenulotomy) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44615/abstract/9\">",
"     9",
"    </a>",
"    ]. Feeding difficulty improved in all of the infants who received immediate division (although one required the use of a nipple shield), but in only one of the infants who received intensive support. Division was offered for the infants in the control group who failed to improve; all parents accepted, and all but one baby improved and fed normally after division.",
"   </p>",
"   <p>",
"    Although this trial was randomized, it was not blinded, and the outcome of interest was subjective (mother's assessment of improvement in breastfeeding). Because there are many factors that affect the ability to breastfeed, it is difficult to ascertain whether the perceived improvement in breastfeeding was due to release of tongue-tie or to other factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44615/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This issue was addressed in another randomized trial in which 25 infants with ankyloglossia (inability to protrude the tongue over the lower gum line and tongue became heart shaped with lifting) and breastfeeding difficulty (nipple pain) were randomly assigned to one of two sequences [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44615/abstract/26\">",
"     26",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Frenotomy followed immediately by breastfeeding, then sham procedure followed immediately by breastfeeding",
"     </li>",
"     <li>",
"      Sham procedure followed immediately by breastfeeding, then frenotomy followed immediately by breastfeeding",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Sham procedure was similar in every respect to frenotomy, except that the scissors were merely placed in the mouth and not used to cut the frenulum. The surgeons were masked regarding the post-procedure evaluation. The mothers and all personnel taking care of the child after each procedure were masked regarding the procedure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44615/abstract/26\">",
"     26",
"    </a>",
"    ]. The evaluation of breastfeeding was performed by a lactation consultant using a visual analogue pain scale (10 points maximum pain) and standardized latch score (10 points minimum difficulties).",
"   </p>",
"   <p>",
"    Pain scores decreased significantly after frenotomy compared to baseline (from 7.1. to 5.3, p = 0.001). Latch scores increased slightly after the procedure (from 6.4 to 6.8, p = 0.06). Pain scores after the sham procedure were not reported. A number of case series report immediate improvement in problems related to breastfeeding following frenotomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44615/abstract/25,27,31-33\">",
"     25,27,31-33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is a lack of consensus among clinicians regarding the need for frenotomy in infants with ankyloglossia and difficulty breastfeeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44615/abstract/2,3,25\">",
"     2,3,25",
"    </a>",
"    ]. Decisions regarding frenotomy are usually made by the clinician(s) and the child's parents, after discussion of the potential benefits and risks of the procedure.",
"   </p>",
"   <p>",
"    We suggest consultation with a lactation specialist as the first step in the management of infants with ankyloglossia and breastfeeding difficulty whose mothers wish to continue breastfeeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44615/abstract/15\">",
"     15",
"    </a>",
"    ]. For infants with ankyloglossia who continue to have problems with breastfeeding despite lactation support, we suggest frenotomy. If frenotomy is undertaken, it should be performed by appropriately trained personnel [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44615/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Articulation issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;Speech therapy may improve articulation problems in some children with ankyloglossia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44615/abstract/15\">",
"     15",
"    </a>",
"    ]. However, speech pathologists have varied opinions regarding this approach [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44615/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The effects of surgical division of ankyloglossia on articulation problems have not been studied in controlled trials. In a case series, articulation problems considered by a speech pathologist to be due to ankyloglossia improved in 9 of 15 children after surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44615/abstract/14\">",
"     14",
"    </a>",
"    ]. Mean tongue protrusion and elevation improved postoperatively compared to baseline (25.8 versus 14.2 mm and 22 mm versus 5.2 mm, respectively).",
"   </p>",
"   <p>",
"    Pediatric otolaryngologists work in concert with speech pathologists in treating children with ankyloglossia and speech problems. Often, children are referred to the otolaryngologist after a full speech assessment and a trial of therapy with a request for surgical division of the frenulum. Most otolaryngologists request input from a speech pathologist before surgery to assess the need for surgery and to document the functional nature of the procedure for third-party payers. Finally, speech therapy may be necessary after surgery to retrain tongue musculature and correct preoperative compensatory strategies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44615/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Other problems",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other problems that may warrant surgical treatment of ankyloglossia include periodontal disease or psychosocial problems [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44615/abstract/1,2,28\">",
"     1,2,28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The effects of surgical division of ankyloglossia on mechanical problems have not been studied in controlled trials. In case series, patients report improvement in mechanical problems following release of tongue tie [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44615/abstract/22,23\">",
"     22,23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Surgical procedures",
"    </span>",
"    &nbsp;&mdash;&nbsp;The two most commonly performed procedures for ankyloglossia are frenotomy and frenuloplasty.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Frenotomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Frenotomy (also called frenulotomy) is simple release, or \"clipping,\" of the frenulum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44615/abstract/15\">",
"     15",
"    </a>",
"    ]. This procedure is often performed for infants with breastfeeding difficulty, with or without local anesthesia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44615/abstract/11,15,22,34\">",
"     11,15,22,34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/18/35114?source=see_link\">",
"     \"Prevention and treatment of neonatal pain\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/23/43384?source=see_link\">",
"     \"Procedural sedation in children outside of the operating room\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a randomized trial, newborn infants with significant ankyloglossia and difficulty breastfeeding underwent frenotomy (n = 30) or sham procedure (n = 28) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44615/abstract/35\">",
"     35",
"    </a>",
"    ]. Immediately after the intervention, nipple pain scores improved significantly in both groups compared with baseline, but to a significantly greater degree in the frenotomy group. Breastfeeding scores improved significantly only in the frenotomy group. Parents were unblinded after the postintervention assessment. All but one parent in the sham group elected to have their infant undergo frenotomy at or before the two-week follow-up visit due to continued breastfeeding difficulties.",
"   </p>",
"   <p>",
"    For completeness and to avoid injury to nearby structures, it is best done under direct vision, rather than by blindly snipping the frenulum. The infant is restrained by swaddling or in a Papoose board, with an assistant holding the child's head. The area is illuminated with a headlight or an office microscope. The tongue is elevated either with forceps, or preferably with two gloved fingers on the underside of the tongue (",
"    <a class=\"graphic graphic_picture graphicRef52382 \" href=\"mobipreview.htm?19/19/19763\">",
"     picture 4",
"    </a>",
"    ). Simple division of the frenulum rarely leads to significant bleeding (",
"    <a class=\"graphic graphic_picture graphicRef58581 \" href=\"mobipreview.htm?32/44/33472\">",
"     picture 5",
"    </a>",
"    ). Pressure with a gauze sponge for a few minutes controls any capillary ooze. The infant may feed immediately after the procedure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44615/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Potential adverse effects of frenulotomy include bleeding, infection, ulceration, pain, damage to the tongue and submandibular ducts, and recurrence. Most studies report little discomfort and few adverse effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44615/abstract/9,26,31,36-38\">",
"     9,26,31,36-38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Frenuloplasty",
"    </span>",
"    &nbsp;&mdash;&nbsp;Frenuloplasty is release of ankyloglossia with plastic repair. It is reserved for ankyloglossia that is not relieved by simple division of the frenulum, very thick frenula, or for revision cases.",
"   </p>",
"   <p>",
"    Frenuloplasty requires general anesthesia, sometimes by mask, but more commonly with oro- or nasotracheal intubation. In this procedure, the tongue is elevated with forceps, and the frenulum is divided in the sagittal plane as in frenulotomy. Submucosal dissection continues into the genioglossus muscle in the midline until a full release is achieved (",
"    <a class=\"graphic graphic_picture graphicRef53120 \" href=\"mobipreview.htm?37/49/38677\">",
"     picture 6",
"    </a>",
"    ). Bipolar electrosurgical scissors or monopolar cautery is preferred for dissection and hemostasis since the tongue musculature is vascular [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44615/abstract/39\">",
"     39",
"    </a>",
"    ]. Good illumination and magnification with loupes or an operating microscope permit division of the frenulum without injury to the nearby submandibular ducts. Midline dissection decreases the risks of injury to the lingual nerves.",
"   </p>",
"   <p>",
"    Frenuloplasty dissection produces an elliptical tissue defect on the floor of the mouth. If left open, scarring and recurrent tethering of the tongue may result. The wound is usually closed with multiple simple absorbable sutures in the coronal plane to achieve a double V-Y advancement. Occasionally, a Z-plasty or a buccal mucosal graft can be used to prevent scar contracture [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44615/abstract/18,40,41\">",
"     18,40,41",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/11/11446?source=see_link\">",
"     \"Z-plasty\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Following surgery, a normal diet can be resumed as tolerated. For patients who can comply, tongue exercises may be suggested postoperatively to enhance mobility, retrain musculature, and reduce the potential for scarring [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44615/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?3/26/3491?source=see_link\">",
"       \"Patient information: Common breastfeeding problems (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?36/61/37845?source=see_link\">",
"       \"Patient information: Common breastfeeding problems (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Clinical features of ankyloglossia (tongue-tie) include inability to lift the tongue to the upper dental alveolus (",
"      <a class=\"graphic graphic_picture graphicRef50442 \" href=\"mobipreview.htm?0/55/882\">",
"       picture 2",
"      </a>",
"      ) and protrude the tongue more than 1 to 2 mm past the lower central incisors (",
"      <a class=\"graphic graphic_picture graphicRef61044 \" href=\"mobipreview.htm?14/53/15184\">",
"       picture 3",
"      </a>",
"      ), impaired side-to-side movement of the tongue, and a notched or heart shape to the tongue when it is protruded (",
"      <a class=\"graphic graphic_figure graphicRef67272 \" href=\"mobipreview.htm?5/57/6032\">",
"       figure 3",
"      </a>",
"      ). The natural history is unknown. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Potential sequelae of ankyloglossia include difficulty breastfeeding, articulation problems, and mechanical problems (eg, inability to lick the lips or sweep food debris from the teeth). Ankyloglossia does not cause speech or language delay. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Potential sequelae'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Indications for surgical release of ankyloglossia may include breastfeeding difficulty, articulation problems, psychologic problems, and periodontal disease. The goal of surgery is increased mobility, not improved contour. The optimal timing for surgery is controversial. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest consultation with a lactation consultant as the first step in the management of infants with ankyloglossia and breastfeeding difficulty whose mothers wish to continue breastfeeding (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). For infants with ankyloglossia who continue to have problems with breastfeeding despite lactation support, we suggest frenotomy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). If frenotomy is undertaken, it should be performed by appropriately trained personnel. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Breastfeeding issues'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Evaluation by a speech pathologist is an essential component of the evaluation of children with ankyloglossia and articulation problems. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Articulation issues'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44615/abstract/1\">",
"      Mueller DT, Callanan VP. Congenital malformations of the oral cavity. Otolaryngol Clin North Am 2007; 40:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44615/abstract/2\">",
"      Messner AH, Lalakea ML. Ankyloglossia: controversies in management. Int J Pediatr Otorhinolaryngol 2000; 54:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44615/abstract/3\">",
"      Brinkmann S, Reilly S, Meara JG. Management of tongue-tie in children: a survey of paediatric surgeons in Australia. J Paediatr Child Health 2004; 40:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44615/abstract/4\">",
"      Hall DM, Renfrew MJ. Tongue tie. Arch Dis Child 2005; 90:1211.",
"     </a>",
"    </li>",
"    <li>",
"     National Institute for Health and Clinical Excellence. Division of ankyloglossia (tongue-tie) for breastfeeding. nice.org.uk/guidance/index.jsp?action=byID&amp;o=11180 (Accessed on June 25, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44615/abstract/6\">",
"      Cinar F, Onat N. Prevalence and consequences of a forgotten entity: ankyloglossia. Plast Reconstr Surg 2005; 115:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44615/abstract/7\">",
"      Messner AH, Lalakea ML, Aby J, et al. Ankyloglossia: incidence and associated feeding difficulties. Arch Otolaryngol Head Neck Surg 2000; 126:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44615/abstract/8\">",
"      Segal LM, Stephenson R, Dawes M, Feldman P. Prevalence, diagnosis, and treatment of ankyloglossia: methodologic review. Can Fam Physician 2007; 53:1027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44615/abstract/9\">",
"      Hogan M, Westcott C, Griffiths M. Randomized, controlled trial of division of tongue-tie in infants with feeding problems. J Paediatr Child Health 2005; 41:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44615/abstract/10\">",
"      Ricke LA, Baker NJ, Madlon-Kay DJ, DeFor TA. Newborn tongue-tie: prevalence and effect on breast-feeding. J Am Board Fam Pract 2005; 18:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44615/abstract/11\">",
"      Ballard JL, Auer CE, Khoury JC. Ankyloglossia: assessment, incidence, and effect of frenuloplasty on the breastfeeding dyad. Pediatrics 2002; 110:e63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44615/abstract/12\">",
"      Garcia-Pola MJ, Garcia-Martin JM, Gonzalez-Garcia M. Prevalence of oral lesions in the 6-year-old pediatric population of Oviedo (Spain). Med Oral 2002; 7:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44615/abstract/13\">",
"      Flinck A, Paludan A, Matsson L, et al. Oral findings in a group of newborn Swedish children. Int J Paediatr Dent 1994; 4:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44615/abstract/14\">",
"      Sedano HO, Carreon Freyre I, Garza de la Garza ML, et al. Clinical orodental abnormalities in Mexican children. Oral Surg Oral Med Oral Pathol 1989; 68:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44615/abstract/15\">",
"      Lalakea ML, Messner AH. Ankyloglossia: does it matter? Pediatr Clin North Am 2003; 50:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44615/abstract/16\">",
"      Ruffoli R, Giambelluca MA, Scavuzzo MC, et al. Ankyloglossia: a morphofunctional investigation in children. Oral Dis 2005; 11:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44615/abstract/17\">",
"      Kantaputra PN, Paramee M, Kaewkhampa A, et al. Cleft lip with cleft palate, ankyloglossia, and hypodontia are associated with TBX22 mutations. J Dent Res 2011; 90:450.",
"     </a>",
"    </li>",
"    <li>",
"     Muntz HR, Gray SD. Congenital malformations of the mouth and pharynx. In: Pediatric otolaryngology, 4th ed, Bluestone CD, Casselbrant ML, Stool SE, et al (Eds), Saunders, Philadelphia 2003. p.1149.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44615/abstract/19\">",
"      WALLACE AF. TONGUE TIE. Lancet 1963; 2:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44615/abstract/20\">",
"      Horton CE, Crawford HH, Adamson JE, Ashbell TS. Tongue-tie. Cleft Palate J 1969; 6:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44615/abstract/21\">",
"      Hong P, Lago D, Seargeant J, et al. Defining ankyloglossia: a case series of anterior and posterior tongue ties. Int J Pediatr Otorhinolaryngol 2010; 74:1003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44615/abstract/22\">",
"      Wright JE. Tongue-tie. J Paediatr Child Health 1995; 31:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44615/abstract/23\">",
"      Lalakea ML, Messner AH. Ankyloglossia: the adolescent and adult perspective. Otolaryngol Head Neck Surg 2003; 128:746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44615/abstract/24\">",
"      Ketty N, Sciullo PA. Ankyloglossia with psychological implications. ASDC J Dent Child 1974; 41:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44615/abstract/25\">",
"      Forlenza GP, Paradise Black NM, McNamara EG, Sullivan SE. Ankyloglossia, exclusive breastfeeding, and failure to thrive. Pediatrics 2010; 125:e1500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44615/abstract/26\">",
"      Dollberg S, Botzer E, Grunis E, Mimouni FB. Immediate nipple pain relief after frenotomy in breast-fed infants with ankyloglossia: a randomized, prospective study. J Pediatr Surg 2006; 41:1598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44615/abstract/27\">",
"      Geddes DT, Langton DB, Gollow I, et al. Frenulotomy for breastfeeding infants with ankyloglossia: effect on milk removal and sucking mechanism as imaged by ultrasound. Pediatrics 2008; 122:e188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44615/abstract/28\">",
"      Messner AH, Lalakea ML. The effect of ankyloglossia on speech in children. Otolaryngol Head Neck Surg 2002; 127:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44615/abstract/29\">",
"      Williams WN, Waldron CM. Assessment of lingual function when ankyloglossia (tongue-tie) is suspected. J Am Dent Assoc 1985; 110:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44615/abstract/30\">",
"      Fiorotti RC, Bertolini MM, Nicola JH, Nicola EM. Early lingual frenectomy assisted by CO2 laser helps prevention and treatment of functional alterations caused by ankyloglossia. Int J Orofacial Myology 2004; 30:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44615/abstract/31\">",
"      Masaitis NS, Kaempf JW. Developing a frenotomy policy at one medical center: a case study approach. J Hum Lact 1996; 12:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44615/abstract/32\">",
"      Marmet C, Shell E, Marmet R. Neonatal frenotomy may be necessary to correct breastfeeding problems. J Hum Lact 1990; 6:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44615/abstract/33\">",
"      Notestine GE. The importance of the identification of ankyloglossia (short lingual frenulum) as a cause of breastfeeding problems. J Hum Lact 1990; 6:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44615/abstract/34\">",
"      Froom SR, Stewart J. Novel local anaesthetic analgesic technique for tongue-tie. Anaesthesia 2007; 62:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44615/abstract/35\">",
"      Buryk M, Bloom D, Shope T. Efficacy of neonatal release of ankyloglossia: a randomized trial. Pediatrics 2011; 128:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44615/abstract/36\">",
"      Griffiths DM. Do tongue ties affect breastfeeding? J Hum Lact 2004; 20:409.",
"     </a>",
"    </li>",
"    <li>",
"     Interventional procedures overview - division of anklyloglossia (tongue-tie) for breastfeeding. www.nice.org.uk/ip279overview (Accessed on June 25, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44615/abstract/38\">",
"      Amir LH, James JP, Beatty J. Review of tongue-tie release at a tertiary maternity hospital. J Paediatr Child Health 2005; 41:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44615/abstract/39\">",
"      Isaacson G. Pediatric intracapsular tonsillectomy with bipolar electrosurgical scissors. Ear Nose Throat J 2004; 83:702, 704.",
"     </a>",
"    </li>",
"    <li>",
"     Kaban LB. Pediatric oral and maxillofacial surgery, WB Saunders, Philadelphia 1990. p.131.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44615/abstract/41\">",
"      Godley FA. Frenuloplasty with a buccal mucosal graft. Laryngoscope 1994; 104:378.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6307 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-11D65C23BF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_36_44615=[""].join("\n");
var outline_f43_36_44615=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15215595\">",
"      &ldquo;Posterior&rdquo; ankyloglossia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      POTENTIAL SEQUELAE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Breastfeeding problems",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Articulation problems",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Mechanical problems",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Potential indications for surgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Breastfeeding issues",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Articulation issues",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Other problems",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Surgical procedures",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Frenotomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Frenuloplasty",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/6307\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/6307|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?9/25/9616\" title=\"figure 1\">",
"      Interincisal distance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?21/1/21535\" title=\"figure 2\">",
"      Tongue protrusion measure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?5/57/6032\" title=\"figure 3\">",
"      Notched tongue",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?8/47/8959\" title=\"figure 4\">",
"      Tongue protrusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/6307|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?2/3/2098\" title=\"picture 1A\">",
"      Abnormally short frenulum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?9/0/9218\" title=\"picture 1B\">",
"      Infant ankyloglossia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?0/55/882\" title=\"picture 2\">",
"      Inability to lift the tongue",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?14/53/15184\" title=\"picture 3\">",
"      Short protrusion of the tongue",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?19/19/19763\" title=\"picture 4\">",
"      Frenulotomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?32/44/33472\" title=\"picture 5\">",
"      Infant status-post frenulotomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?37/49/38677\" title=\"picture 6\">",
"      Frenuloplasty for ankyloglossia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/39/42616?source=related_link\">",
"      Breastfeeding: Parental education and support",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/15/17658?source=related_link\">",
"      Common problems of breastfeeding and weaning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/59/1977?source=related_link\">",
"      Congenital anomalies of the jaw, mouth, oral cavity, and pharynx",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/46/26343?source=related_link\">",
"      Evaluation and treatment of speech and language disorders in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/45/32471?source=related_link\">",
"      Overview of gingivitis and periodontitis in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?36/61/37845?source=related_link\">",
"      Patient information: Common breastfeeding problems (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?3/26/3491?source=related_link\">",
"      Patient information: Common breastfeeding problems (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/18/35114?source=related_link\">",
"      Prevention and treatment of neonatal pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/23/43384?source=related_link\">",
"      Procedural sedation in children outside of the operating room",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/4/21576?source=related_link\">",
"      Sucking and swallowing disorders in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/11/11446?source=related_link\">",
"      Z-plasty",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f43_36_44616="Treatment of benign (WHO grade I) meningioma";
var content_f43_36_44616=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of benign (WHO grade I) meningioma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/36/44616/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/36/44616/contributors\">",
"     John K Park, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/36/44616/contributors\">",
"     Peter McLaren Black, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/36/44616/contributors\">",
"     Helen A Shih, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/36/44616/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/36/44616/contributors\">",
"     Jay S Loeffler, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/36/44616/contributors\">",
"     Patrick Y Wen, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/36/44616/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/36/44616/contributors\">",
"     April F Eichler, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?43/36/44616/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 1, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Meningiomas account for approximately one-third of primary central nervous system tumors (",
"    <a class=\"graphic graphic_table graphicRef81566 \" href=\"mobipreview.htm?6/44/6862\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef72275 \" href=\"mobipreview.htm?28/44/29391\">",
"     figure 1",
"    </a>",
"    ). Although most meningiomas are benign (WHO grade I), their location in the central nervous system can cause serious morbidity",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    mortality. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/59/2997?source=see_link\">",
"     \"Incidence of primary brain tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The management of patients with meningioma requires a balance between definitive treatment of the tumor and avoidance of neurologic damage from the treatment. Patient-specific factors (presence or absence of symptoms, age, comorbidity), the location of the meningioma in relation to critical brain structures and regions, and the histopathologic characteristics (WHO grade) of the meningioma all are important factors in determining the optimal treatment.",
"   </p>",
"   <p>",
"    Depending upon these characteristics, initial management for patients with a benign (WHO grade I) meningioma may consist of surgery, surgery plus radiation therapy, or radiation therapy alone. In addition, for some patients with small, asymptomatic or minimally symptomatic lesions patients may simply be monitored for evidence of tumor growth, with initial treatment deferred.",
"   </p>",
"   <p>",
"    The initial management of benign (WHO grade I) meningiomas will be reviewed here. Related topics regarding the management of meningioma include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/54/20328?source=see_link\">",
"       \"Meningioma: Epidemiology, risk factors, and pathology\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/60/25540?source=see_link\">",
"       \"Meningioma: Clinical presentation and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/25/42389?source=see_link\">",
"       \"Atypical and malignant meningiomas\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/2/4133?source=see_link\">",
"       \"Systemic treatment of recurrent meningioma\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ACTIVE SURVEILLANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many meningiomas are discovered incidentally on a neuroimaging study (MRI, CT) obtained for symptoms unrelated to the tumor. Such tumors may remain unchanged in size or grow only very slowly over prolonged periods. As a result, most patients with small asymptomatic meningiomas can be safely observed; treatment is instituted only if the tumor enlarges significantly or becomes symptomatic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44616/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The rationale for active surveillance is illustrated by a retrospective Japanese study of 1434 patients with meningioma, who were diagnosed between 1989 and 2003 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44616/abstract/3\">",
"     3",
"    </a>",
"    ]. In this series, 603 patients (42 percent) were asymptomatic and 351 of these were managed with observation. Of the 171 patients followed for more than one year, 31 were subsequently treated with either surgery or stereotactic radiosurgery (SRS), in most cases due to tumor growth. Among the 67 asymptomatic patients with follow-up of more than five years, 63 percent did not have evidence of tumor growth. Among the 213 asymptomatic patients treated surgically, morbidity occurred in 4 percent of those less than 70 years of age and in 9 percent of those &ge;70 years. These data suggest that a large proportion of asymptomatic patients do not become symptomatic in the short-term, providing a rationale for active surveillance.",
"   </p>",
"   <p>",
"    Our approach to the management of small, asymptomatic meningiomas is to reassess the patient with MRI or CT after three to six months. If the patient remains asymptomatic and there is no evidence of tumor growth, the patient can then be monitored with neuroimaging on an annual basis.",
"   </p>",
"   <p>",
"    This approach is particularly suitable for older patients and those with significant comorbidity. For relatively healthy younger patients, there is a lower threshold for therapeutic intervention because of the expectation that tumor progression will inevitably require active treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44616/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     SURGERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptomatic meningiomas and asymptomatic tumors that are expanding, infiltrating, or associated with surrounding edema should be surgically resected if feasible. Complete surgical resection is preferred when a meningioma is in an accessible location, since complete resection of the tumor and its dural attachment can be curative.",
"   </p>",
"   <p>",
"    Multiple advances in neurosurgery, including microsurgery, improved preoperative imaging, and intraoperative image-guided approaches, have extended the neurosurgeon's ability to resect lesions that were previously considered only partially resectable or unresectable, while minimizing damage to normal brain.",
"   </p>",
"   <p>",
"    Surgery is often combined with radiation therapy (RT) for less accessible lesions when a complete resection is not feasible. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'RT after subtotal resection'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Surgery is also combined with RT in the initial management of atypical and malignant meningiomas (WHO grades II and III) because the risk of recurrence is high and negative surgical margins cannot be assured. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/25/42389?source=see_link&amp;anchor=H444764643#H444764643\">",
"     \"Atypical and malignant meningiomas\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Extent of resection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Observational studies have reported that complete resection, when feasible, was associated with significantly prolonged survival compared to partial resection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44616/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. Complete surgical resection should include the dural attachment of the meningioma.",
"   </p>",
"   <p>",
"    The Simpson grading system has been used to describe the extent of surgical resection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44616/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Grade 1, complete resection, including the dural attachment and any abnormal bone",
"     </li>",
"     <li>",
"      Grade 2, complete resection, with coagulation of the dural attachment",
"     </li>",
"     <li>",
"      Grade 3, complete resection, without resection or coagulation of the dural attachment",
"     </li>",
"     <li>",
"      Grade 4, subtotal resection",
"     </li>",
"     <li>",
"      Grade 5, tumor decompression only",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Studies demonstrating the survival advantage from complete resection generally antedate the adjuvant use of radiation therapy (RT) with contemporary conformal techniques for patients with residual disease. The use of modern adjuvant RT techniques to treat residual disease appears to yield results comparable to more aggressive surgery and can minimize treatment-related neurologic deficits. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'RT after subtotal resection'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In contemporary practice, the goal of surgery is to achieve as extensive a resection as possible while minimizing neurologic deficits. The extent of resection varies depending upon the location of the tumor, whether there is imaging evidence of invasion, and the presurgical status of the patient (neurologic deficits, comorbidity).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Complete resection is usually attempted for tumors of the convexity, olfactory groove, anterior third of the sagittal sinus, and some tentorial and posterior fossa tumors.",
"     </li>",
"     <li>",
"      Partial resection rather than complete resection may be more appropriate for less accessible tumors, such as those involving the posterior sagittal region or clivus. Residual tumor can be treated postoperatively with RT. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Radiation therapy'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Biopsy alone or treatment without a tissue diagnosis may be needed for inaccessible tumors such as those involving the medial sphenoid wing or cavernous sinus. Definitive RT is the treatment of choice in these cases. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Radiation therapy'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Because meningiomas are vascular tumors, preoperative embolization may be useful to increase resectability in carefully selected patients with skull base meningiomas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44616/abstract/8-11\">",
"     8-11",
"    </a>",
"    ]. When indicated, this procedure can be performed the day prior to surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Surgical morbidity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postoperative neurologic deficits can be a direct complication of surgery. The reported incidence of such neurologic deficits ranges from 2 to 30 percent depending upon the location of the tumor and the extent of the resection. Cortical brain injury may occur if the arachnoid and pia are adherent to the tumor and there is disruption of the pial vasculature with subsequent cortical microinfarction. Cranial nerve deficits are a risk in surgery for skull base meningiomas, and intraoperative cranial nerve monitoring should be used for tumors located near the cranial nerves.",
"   </p>",
"   <p>",
"    The reported overall surgical mortality has varied widely, reflecting differences in patient selection criteria as well as changes in surgical care. Factors associated with an increased mortality included poor preoperative clinical condition, brain compression from tumor, advanced age, incomplete tumor removal, and intracranial hematoma requiring evacuation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44616/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Older series indicated that the mortality was higher in elderly patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44616/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. More recent series, using contemporary neurosurgical techniques, have shown that surgery is feasible in carefully selected elderly patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44616/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. As an example, there was no perioperative mortality in a carefully selected series of 74 patients aged &ge;80 years, and the incidence of postoperative complications was only 9 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44616/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Perioperative medical management",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to neurologic deficits that are a direct consequence of surgery, common medical complications include seizures, deep venous thrombosis, pulmonary embolism, pneumonia, myocardial infarction, and arrhythmias.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Seizures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Seizures are a frequent presenting symptom of meningiomas. Seizures can also occur in the postoperative period.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prophylactic anticonvulsants are generally not indicated prior to treatment in patients without a history of seizures. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/16/18697?source=see_link&amp;anchor=H4#H4\">",
"       \"Seizures in patients with primary and metastatic brain tumors\", section on 'Prophylaxis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients undergoing surgery for supratentorial tumors should be placed on prophylactic anticonvulsants postoperatively. In patients who have not had a seizure, anticonvulsants should be gradually tapered and then discontinued. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/16/18697?source=see_link&amp;anchor=H6#H6\">",
"       \"Seizures in patients with primary and metastatic brain tumors\", section on 'Postoperative prophylaxis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Cerebral edema",
"    </span>",
"    &nbsp;&mdash;&nbsp;Standard preoperative medications include corticosteroids to reduce brain edema. During the surgical procedure,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/42/3752?source=see_link\">",
"     mannitol",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/52/28488?source=see_link\">",
"     furosemide",
"    </a>",
"    are administered and the arterial PCO2 is lowered to 30 mmHg to reduce intracranial pressure if the tumor is large or if significant brain retraction is anticipated. Corticosteroids are tapered postoperatively. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/26/39335?source=see_link\">",
"     \"Management of vasogenic edema in patients with primary and metastatic brain tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Deep venous thrombosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Deep venous thrombosis (DVT) is especially problematic both because the thromboembolic risk in general is increased in patients undergoing brain surgery and because meningiomas can produce a hypercoagulable state. In one small series, for example, almost three-fourths of patients had evidence of postoperative DVT following surgery for intracranial meningioma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44616/abstract/15\">",
"     15",
"    </a>",
"    ]. The hemostatic disorder in these patients resembles a chronic subclinical form of disseminated intravascular coagulation (DIC) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44616/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/12/1224?source=see_link\">",
"     \"Pathogenesis of the hypercoagulable state associated with malignancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/43/35514?source=see_link\">",
"     \"Hypercoagulable disorders associated with malignancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Prophylactic anticoagulation may lower the risk of thromboembolic events and should be considered in the postoperative period for all patients with brain tumors. Subcutaneous low-molecular-weight",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    is recommended postoperatively for patients requiring craniotomy for removal of a meningioma. In addition, pneumatic compression boots should be used until the patient is ambulatory. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/39/30327?source=see_link\">",
"     \"Anticoagulant and antiplatelet therapy in patients with brain tumors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/52/41802?source=see_link\">",
"     \"Prevention of venous thromboembolic disease in surgical patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     RADIATION THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiation therapy (RT) has an important role in the management of meningiomas that have been subtotally resected or are unresectable because of their proximity to critical neurologic structures.",
"   </p>",
"   <p>",
"    RT is also used in some cases after presumed complete resection of atypical or malignant meningiomas, which otherwise have a high rate of local recurrence. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/25/42389?source=see_link&amp;anchor=H444764643#H444764643\">",
"     \"Atypical and malignant meningiomas\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     RT after subtotal resection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although there are no randomized trials that assess the role of RT, observational studies indicate that RT after a partial resection of a meningioma substantially improves progression-free survival compared to partial resection alone and may be as effective as complete resection. Whether this approach improves overall survival compared to reserving use of RT until there is evidence of a recurrence is unclear.",
"   </p>",
"   <p>",
"    Accurate delineation of the residual tumor following surgery using contemporary imaging studies is critical for optimal results with postoperative RT.",
"   </p>",
"   <p>",
"    The importance of imaging in defining RT fields was illustrated by a retrospective analysis from the University of California at San Francisco, which included 140 patients who underwent a subtotal resection of an intracranial meningioma between 1967 and 1990 and were then treated with postoperative RT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44616/abstract/17\">",
"     17",
"    </a>",
"    ]. For patients treated between 1967 and 1980, RT treatment volumes were based exclusively upon the surgeon's assessment of the site and volume of residual disease. From 1981 through 1990, RT treatment volumes incorporated information about residual tumor from CT",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    MRI. Among the 117 patients with benign meningiomas, the use of CT",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    MRI to plan the postoperative RT was associated with a significant improvement in the five-year progression-free survival (98 versus 77 percent).",
"   </p>",
"   <p>",
"    Retrospective data from other groups also supports the role of RT in patients who have undergone subtotal resection of meningiomas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44616/abstract/18-20\">",
"     18-20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     RT alone for nonresectable meningiomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;RT alone can be effective in treating meningiomas that are not amenable to even a subtotal resection, providing excellent tumor control and avoiding the risks of surgery. The role of RT in this setting is illustrated by the following examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one series, 101 patients with presumed benign skull base meningiomas were treated with fractionated radiation alone (66 cases) or after subtotal resection (35 patients) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/36/44616/abstract/21\">",
"       21",
"      </a>",
"      ]. Median follow up was five years. Local control rates for all patients were 95 percent at five years, and 92 percent at both 10 and 15 years.",
"     </li>",
"     <li>",
"      In another retrospective series, 41 patients (with 42 meningiomas) were treated with RT without any surgery [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/36/44616/abstract/22\">",
"       22",
"      </a>",
"      ]. RT consisted for stereotactic radiosurgery, stereotactic radiotherapy, or three-dimensional conformal RT in 22, 11, and 9 cases, respectively. At a median follow-up of five years, local control was achieved in 39 cases (93 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Dosage and toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;When RT is used postoperatively to treat residual disease, a dose of 54 Gy in daily fractions of 1.8 to 2 Gy is generally used for benign meningiomas. Higher doses are generally recommended for WHO grade II and III meningiomas. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/25/42389?source=see_link&amp;anchor=H537373725#H537373725\">",
"     \"Atypical and malignant meningiomas\", section on 'Radiation therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The importance of the radiation dose is illustrated by a retrospective series of 140 patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44616/abstract/17,23\">",
"     17,23",
"    </a>",
"    ]. Among the 117 patients with benign meningiomas, those treated to doses &gt;52 Gy had a better 10-year progression-free survival (93 versus 65 percent with &le;52 Gy).",
"   </p>",
"   <p>",
"    Potential adverse effects of external beam radiation on the surrounding normal brain are rarely seen at using daily fractions of 1.8 to 2.0 Gy to a total dose of 54 Gy and are uncommon at doses up to 59.4 Gy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/22/37226?source=see_link\">",
"     \"Complications of cranial irradiation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H444767541\">",
"    <span class=\"h2\">",
"     RT technical advances",
"    </span>",
"    &nbsp;&mdash;&nbsp;Newer conformal RT techniques, including stereotactic radiosurgery (SRS), fractionated stereotactic radiotherapy (SRT), intensity-modulated radiation therapy (IMRT), and proton radiotherapy, are important for the delivery of radiation to meningiomas that are in close proximity to critical structures such as the optic nerve, while minimizing radiation to normal brain structures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H444767548\">",
"    <span class=\"h3\">",
"     Stereotactic radiosurgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stereotactic radiosurgery (SRS) utilizes multiple convergent beams to deliver a high single dose of radiation to a radiographically discrete treatment volume, thereby minimizing injury to adjacent structures. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/5/32855?source=see_link\">",
"     \"Stereotactic cranial radiosurgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    SRS is an alternative to surgery for small tumors in selected sites where complete excision is difficult or in patients at high risk for surgical resection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44616/abstract/24-28\">",
"     24-28",
"    </a>",
"    ]. Although no randomized trials have been completed comparing SRS to surgery or other radiotherapy techniques, the outcomes appear to be similar to surgery for small to medium-sized meningiomas. In three large series, involving overall almost 400 patients with cavernous sinus meningiomas treated with SRS to a dose of 12 to 14 Gy, the five-year tumor control rate ranged from 94 to 98 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44616/abstract/24,29,30\">",
"     24,29,30",
"    </a>",
"    ]. If doses above 18 Gy are used, there is a significant risk of toxicity to cranial nerves within the cavernous sinus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H444767555\">",
"    <span class=\"h3\">",
"     Stereotactic radiotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stereotactic radiotherapy (SRT) uses focused radiation in the same way as SRS but fractionates the radiation over a series of sessions. Fractionation improves normal tissue tolerance of radiation, and SRT may be a reasonable alternative for patients with surgically inaccessible lesions, either as postoperative therapy following subtotal resection or to treat local recurrence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44616/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/5/32855?source=see_link\">",
"     \"Stereotactic cranial radiosurgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    SRT may be particularly useful for patients with optic nerve sheath meningiomas, in whom surgery can cause postoperative blindness. In multiple small series, SRT resulted in preservation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    improvement in vision in approximately 80 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44616/abstract/33\">",
"     33",
"    </a>",
"    ]. SRT also appears to be useful in those with small meningiomas of the skull base [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44616/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H444767562\">",
"    <span class=\"h3\">",
"     Intensity-modulated RT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intensity-modulated RT (IMRT) is a technique that relies upon software and modification of standard linear accelerator output to vary the radiation intensity across each treatment field. IMRT may be particularly useful for patients with meningiomas when the target is juxtaposed to radiation-sensitive structures or has a particularly complex shape, such as those involving the skull base [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44616/abstract/35\">",
"     35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/55/32630?source=see_link\">",
"     \"Intensity-modulated radiation therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H444767569\">",
"    <span class=\"h3\">",
"     Proton beam",
"    </span>",
"    &nbsp;&mdash;&nbsp;Heavy particles, such as protons and carbon ion beam, are not widely available but may have some utility in treating patients with meningioma when a highly conformal radiation field is required [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44616/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. Additional experience is required to determine whether or not these approaches offer any benefit compared to other contemporary conformal techniques.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H444768026\">",
"    <span class=\"h1\">",
"     ONCOLOGIC AND FUNCTIONAL OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;The results of treatment vary depending upon the location of the meningioma as well as the therapeutic approach. There are no randomized trials comparing different approaches.",
"   </p>",
"   <p>",
"    Optimal therapy needs to be individualized, based upon the anatomic location of the tumor and patient-specific considerations. Results are discussed for three meningioma locations, convexity meningiomas (which usually can be managed with surgery alone), skull base lesions (which often require a multidisciplinary approach), and optic nerve sheath meningiomas (for which RT is often used alone), as well as the limited data available for treatment of radiation-induced meningiomas.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H444768033\">",
"    <span class=\"h2\">",
"     Convexity meningiomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Results with surgery primarily as a single modality are illustrated by a series of 163 patients with convexity meningiomas treated by a single surgeon over a 20-year period [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44616/abstract/38\">",
"     38",
"    </a>",
"    ]. This cohort represented 22 percent of all meningiomas operated on during that period.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      On pathologic examination, 88 percent of lesions were benign (WHO grade I), 10 percent were atypical (WHO grade II), and 2 percent were anaplastic (WHO grade III).",
"     </li>",
"     <li>",
"      There were seven recurrences in the entire series (4 percent). For patients with WHO grade I, II, and III lesions, the five-year recurrence rates were 2, 27, and 50 percent, respectively, although these rates may increase with longer follow-up. The two benign meningiomas that recurred both had features of atypia and a high proliferative index.",
"     </li>",
"     <li>",
"      There were no deaths within 30 days after surgery. The overall complication rate was 9 percent. Three patients had new neurologic deficits postoperatively, all of which represented worsening of motor weakness that was present preoperatively in patients with large (&gt;4 cm) tumors.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H444768040\">",
"    <span class=\"h2\">",
"     Skull base meningiomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of patients with skull base meningiomas is difficult because these lesions generally have an indolent history with only mild symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44616/abstract/39\">",
"     39",
"    </a>",
"    ]. At the same time, radical surgery is associated with substantial morbidity because of the involvement of critical vascular structures, cranial nerves,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    brainstem. Because of these technical issues, there is a higher frequency of local recurrence.",
"   </p>",
"   <p>",
"    The results of a combined modality approach are illustrated by a single surgeon series of 100 consecutive patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44616/abstract/39\">",
"     39",
"    </a>",
"    ]. Patients with minimal or no symptoms were initially managed with observation. Aggressive surgical resection was indicated for patients with a symptomatic tumor, for those with edema and mass effect, or progressive tumor enlargement. Conformal RT or stereotactic radiosurgery (SRS) was used for treatment of residual tumor following surgery or in those patients for whom surgical resection was contraindicated or refused.",
"   </p>",
"   <p>",
"    Treatment included surgery in 72 cases, including 27 in which surgery was followed by radiation. Radiation alone was used in 13 cases and 15 patients were managed with observation. At a median follow-up of five years, only one patient had evidence of tumor progression using this treatment paradigm. There were no treatment-related deaths, and serious complications from surgery were limited to hemiparesis, new cranial nerve palsy, and osteomyelitis (2.8, 2.8, and 1.4 percent of surgical cases, respectively).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H444768047\">",
"    <span class=\"h2\">",
"     Optic nerve sheath meningiomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;RT, using either conventional or stereotactic techniques, can be effective as the primary treatment modality for optic nerve sheath meningiomas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44616/abstract/33,40-42\">",
"     33,40-42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      As an example, either conventional or stereotactic RT was used to treat a series of 34 consecutive patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/36/44616/abstract/40\">",
"       40",
"      </a>",
"      ]. Vision was improved in 14 patients and stabilized in 17 (41 and 50 percent, respectively) following RT. Long-term complications included dry eyes, cataracts, and radiation retinopathy in 15, 9, and 12 percent of cases.",
"     </li>",
"     <li>",
"      In another series, 32 patients were treated with stereotactic fractionated RT [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/36/44616/abstract/42\">",
"       42",
"      </a>",
"      ]. RT was given primary therapy in 15 and followed either biopsy or resection in 10. In seven cases, RT was used to treat recurrent disease. At a median follow-up of 4.5 years, six patients had a partial response (19 percent) and 26 (81 percent) had stable disease. Improvement in visual symptoms was seen in 11 cases (38 percent), while one patient had worsening of vision.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H444768054\">",
"    <span class=\"h2\">",
"     Radiation-induced meningiomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are only limited data available for the treatment of radiation-induced meningiomas. The available evidence suggests that these should be managed in the same fashion as other meningiomas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44616/abstract/43,44\">",
"     43,44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although surgery is the preferred modality, RT techniques may be an option for patients whose tumors arise in critical locations or who are poor candidates for surgery. In this setting, the use of RT must consider the prior radiation dosage to the brain in planning treatment. In a series of 19 patients with 24 meningiomas diagnosed at a median of 30 years after their original treatment, stereotactic radiosurgery resulted in a disease-control rate of 75 percent at a median follow-up of 44 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44616/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H444768061\">",
"    <span class=\"h2\">",
"     Quality of life",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous factors can affect the outcome and recovery following treatment for a meningioma, including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Neurologic damage from the tumor itself, which is dependent upon the anatomic location of the tumor, as well as whether the tumor is locally invasive. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/60/25540?source=see_link&amp;anchor=H12#H12\">",
"       \"Meningioma: Clinical presentation and diagnosis\", section on 'Clinical presentation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Surgical complications. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Surgical morbidity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Risks of radiation, which can produce a range of symptoms with greater permanence in delayed effects such as neurocognitive impairment. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/22/37226?source=see_link\">",
"       \"Complications of cranial irradiation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Side effects of medications used to control symptoms, especially anticonvulsants. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/39/40570?source=see_link&amp;anchor=H8#H8\">",
"       \"Overview of the management of epilepsy in adults\", section on 'Side effects of therapy'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/61/43994?source=see_link\">",
"       \"Pharmacology of antiepileptic drugs\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The overall impact of diagnosis and treatment on quality of life was studied in a single-surgeon series of 200 patients operated on for intracranial meningioma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44616/abstract/45\">",
"     45",
"    </a>",
"    ]. At a mean follow-up of 33 months, 36 patients had died within the first five years, including 18 due to the meningioma. Another eight patients died secondary to the meningioma after another five years. Among the patients still living at the time of analysis, 80 percent were satisfied with their posttreatment quality of life, based upon a self-reported questionnaire.",
"   </p>",
"   <p>",
"    The late impact of disease and treatment on neurocognitive function was studied at least one year after treatment in 89 patients who had been operated on for a grade I meningioma, including 22 who also received RT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44616/abstract/46\">",
"     46",
"    </a>",
"    ]. Compared to matched healthy controls, patients had statistically significant impairment in several neurocognitive areas including executive functioning, verbal memory, information processing capacity, psychomotor speed, and working memory. Factors that appeared to partially account for these deficits include the use of anticonvulsants and the location of the tumor, but not the use of RT.",
"   </p>",
"   <p>",
"    Neurocognitive impairment can be delayed after cranial irradiation and longer follow-up is required to definitively address this issue. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/22/37226?source=see_link&amp;anchor=H20#H20\">",
"     \"Complications of cranial irradiation\", section on 'Neurocognitive effects in adults'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SURVEILLANCE AFTER INITIAL TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cranial imaging (preferably MRI) is used following initial treatment to monitor for evidence of recurrence or for progression of residual disease. There are no studies that define the optimal schedule for such imaging.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For asymptomatic or minimally symptomatic patients managed with active surveillance, our approach is to repeat the imaging procedure in three to six months and then annually if there is no evidence of progression. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Active surveillance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients whose initial management consisted of surgery",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      RT, factors influencing the frequency of repeat imaging include the completeness of resection, the location of the tumor, and its pathology (WHO grade I versus grade II or III). In general, imaging should be repeated in the postoperative period, and then annually, so that any evidence of recurrent or progressive disease can be detected while the disease burden is relatively limited.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     RECURRENT DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most recurrences of meningioma are local or adjacent to a radiation treatment field. Metastases of cranial meningiomas to the spinal cord due to spreading through the cerebrospinal fluid are rare and are more frequently associated with atypical or malignant meningiomas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44616/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. There are only isolated case reports of metastases outside the central nervous system [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44616/abstract/49,50\">",
"     49,50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For patients who recur locally after their initial treatment, additional surgery",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    RT (SRS, SRT, combined proton and photon RT) can sometimes provide effective therapy and occasionally permit long-term recurrence-free survival. The principles underlying the use of surgery or radiation are similar to those for patients presenting de novo, but appropriate management requires a consideration of the effects of prior surgery",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    RT. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Surgery'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H11\">",
"     'Radiation therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?5/15/5362?source=see_link\">",
"       \"Patient information: Meningioma (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H444768437\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The management of patients with meningioma requires a delicate balance between definitive treatment of the tumor and avoidance of neurologic damage from the treatment. Patient-related factors (symptomatology, age, comorbidity, the anatomic location of the meningioma) and the degree of atypia or malignancy of the tumor all are important factors in determining the optimal approach to management. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/54/20328?source=see_link&amp;anchor=H627075368#H627075368\">",
"       \"Meningioma: Epidemiology, risk factors, and pathology\", section on 'Pathology'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with small, asymptomatic meningiomas without edema or imaging evidence of invasion, we suggest careful observation without surgery or radiation therapy (RT) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Our approach is to repeat imaging in three to six months, and then annually thereafter. If there is subsequent evidence of tumor growth, we suggest active treatment with surgery",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      RT. For younger patients in good overall medical condition, early definitive intervention is an appropriate alternative to active surveillance. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Active surveillance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with meningiomas that are symptomatic, large, infiltrating, or associated with substantial edema require definitive treatment with surgery",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      RT. The initial treatment approach (complete surgical resection, subtotal resection with or without RT, or RT alone) should be based upon the overall condition of the patient, the anatomic location of the tumor, the grade of the tumor (WHO grade I, II, or III), and the completeness of any surgical resection. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Surgery'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Radiation therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Perioperative management in patients undergoing surgical resection requires careful attention to prevent complications from cerebral edema, deep venous thrombosis, and seizures. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Seizures'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Cerebral edema'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Deep venous thrombosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44616/abstract/1\">",
"      Go RS, Taylor BV, Kimmel DW. The natural history of asymptomatic meningiomas in Olmsted County, Minnesota. Neurology 1998; 51:1718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44616/abstract/2\">",
"      Nakamura M, Roser F, Michel J, et al. The natural history of incidental meningiomas. Neurosurgery 2003; 53:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44616/abstract/3\">",
"      Yano S, Kuratsu J, Kumamoto Brain Tumor Research Group. Indications for surgery in patients with asymptomatic meningiomas based on an extensive experience. J Neurosurg 2006; 105:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44616/abstract/4\">",
"      Herscovici Z, Rappaport Z, Sulkes J, et al. Natural history of conservatively treated meningiomas. Neurology 2004; 63:1133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44616/abstract/5\">",
"      SIMPSON D. The recurrence of intracranial meningiomas after surgical treatment. J Neurol Neurosurg Psychiatry 1957; 20:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44616/abstract/6\">",
"      Stafford SL, Perry A, Suman VJ, et al. Primarily resected meningiomas: outcome and prognostic factors in 581 Mayo Clinic patients, 1978 through 1988. Mayo Clin Proc 1998; 73:936.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44616/abstract/7\">",
"      Kallio M, Sankila R, Hakulinen T, J&auml;&auml;skel&auml;inen J. Factors affecting operative and excess long-term mortality in 935 patients with intracranial meningioma. Neurosurgery 1992; 31:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44616/abstract/8\">",
"      Oka H, Kurata A, Kawano N, et al. Preoperative superselective embolization of skull-base meningiomas: indications and limitations. J Neurooncol 1998; 40:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44616/abstract/9\">",
"      Rosen CL, Ammerman JM, Sekhar LN, Bank WO. Outcome analysis of preoperative embolization in cranial base surgery. Acta Neurochir (Wien) 2002; 144:1157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44616/abstract/10\">",
"      Carli DF, Sluzewski M, Beute GN, van Rooij WJ. Complications of particle embolization of meningiomas: frequency, risk factors, and outcome. AJNR Am J Neuroradiol 2010; 31:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44616/abstract/11\">",
"      Dowd CF, Halbach VV, Higashida RT. Meningiomas: the role of preoperative angiography and embolization. Neurosurg Focus 2003; 15:E10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44616/abstract/12\">",
"      Awad IA, Kalfas I, Hahn JF, Little JR. Intracranial meningiomas in the aged: surgical outcome in the era of computed tomography. Neurosurgery 1989; 24:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44616/abstract/13\">",
"      Black P, Kathiresan S, Chung W. Meningioma surgery in the elderly: a case-control study assessing morbidity and mortality. Acta Neurochir (Wien) 1998; 140:1013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44616/abstract/14\">",
"      Sacko O, Sesay M, Roux FE, et al. Intracranial meningioma surgery in the ninth decade of life. Neurosurgery 2007; 61:950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44616/abstract/15\">",
"      Sawaya R, Zuccarello M, Elkalliny M, Nishiyama H. Postoperative venous thromboembolism and brain tumors: Part I. Clinical profile. J Neurooncol 1992; 14:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44616/abstract/16\">",
"      Sawaya R, Glas-Greenwalt P. Postoperative venous thromboembolism and brain tumors: Part II. Hemostatic profile. J Neurooncol 1992; 14:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44616/abstract/17\">",
"      Goldsmith BJ, Wara WM, Wilson CB, Larson DA. Postoperative irradiation for subtotally resected meningiomas. A retrospective analysis of 140 patients treated from 1967 to 1990. J Neurosurg 1994; 80:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44616/abstract/18\">",
"      Glaholm J, Bloom HJ, Crow JH. The role of radiotherapy in the management of intracranial meningiomas: the Royal Marsden Hospital experience with 186 patients. Int J Radiat Oncol Biol Phys 1990; 18:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44616/abstract/19\">",
"      Forbes AR, Goldberg ID. Radiation therapy in the treatment of meningioma: the Joint Center for Radiation Therapy experience 1970 to 1982. J Clin Oncol 1984; 2:1139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44616/abstract/20\">",
"      Taylor BW Jr, Marcus RB Jr, Friedman WA, et al. The meningioma controversy: postoperative radiation therapy. Int J Radiat Oncol Biol Phys 1988; 15:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44616/abstract/21\">",
"      Mendenhall WM, Morris CG, Amdur RJ, et al. Radiotherapy alone or after subtotal resection for benign skull base meningiomas. Cancer 2003; 98:1473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44616/abstract/22\">",
"      Korah MP, Nowlan AW, Johnstone PA, Crocker IR. Radiation therapy alone for imaging-defined meningiomas. Int J Radiat Oncol Biol Phys 2010; 76:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44616/abstract/23\">",
"      Barbaro NM, Gutin PH, Wilson CB, et al. Radiation therapy in the treatment of partially resected meningiomas. Neurosurgery 1987; 20:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44616/abstract/24\">",
"      Lee JY, Niranjan A, McInerney J, et al. Stereotactic radiosurgery providing long-term tumor control of cavernous sinus meningiomas. J Neurosurg 2002; 97:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44616/abstract/25\">",
"      Hakim R, Alexander E 3rd, Loeffler JS, et al. Results of linear accelerator-based radiosurgery for intracranial meningiomas. Neurosurgery 1998; 42:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44616/abstract/26\">",
"      Nicolato A, Foroni R, Alessandrini F, et al. Radiosurgical treatment of cavernous sinus meningiomas: experience with 122 treated patients. Neurosurgery 2002; 51:1153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44616/abstract/27\">",
"      Kondziolka D, Flickinger JC, Perez B. Judicious resection and/or radiosurgery for parasagittal meningiomas: outcomes from a multicenter review. Gamma Knife Meningioma Study Group. Neurosurgery 1998; 43:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44616/abstract/28\">",
"      Pollock BE, Stafford SL, Link MJ, et al. Single-fraction radiosurgery for presumed intracranial meningiomas: efficacy and complications from a 22-year experience. Int J Radiat Oncol Biol Phys 2012; 83:1414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44616/abstract/29\">",
"      Spiegelmann R, Cohen ZR, Nissim O, et al. Cavernous sinus meningiomas: a large LINAC radiosurgery series. J Neurooncol 2010; 98:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44616/abstract/30\">",
"      Skeie BS, Enger PO, Skeie GO, et al. Gamma knife surgery of meningiomas involving the cavernous sinus: long-term follow-up of 100 patients. Neurosurgery 2010; 66:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44616/abstract/31\">",
"      Debus J, Wuendrich M, Pirzkall A, et al. High efficacy of fractionated stereotactic radiotherapy of large base-of-skull meningiomas: long-term results. J Clin Oncol 2001; 19:3547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44616/abstract/32\">",
"      Milker-Zabel S, Zabel A, Schulz-Ertner D, et al. Fractionated stereotactic radiotherapy in patients with benign or atypical intracranial meningioma: long-term experience and prognostic factors. Int J Radiat Oncol Biol Phys 2005; 61:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44616/abstract/33\">",
"      Arvold ND, Lessell S, Bussiere M, et al. Visual outcome and tumor control after conformal radiotherapy for patients with optic nerve sheath meningioma. Int J Radiat Oncol Biol Phys 2009; 75:1166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44616/abstract/34\">",
"      Minniti G, Amichetti M, Enrici RM. Radiotherapy and radiosurgery for benign skull base meningiomas. Radiat Oncol 2009; 4:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44616/abstract/35\">",
"      Milker-Zabel S, Zabel-du Bois A, Huber P, et al. Intensity-modulated radiotherapy for complex-shaped meningioma of the skull base: long-term experience of a single institution. Int J Radiat Oncol Biol Phys 2007; 68:858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44616/abstract/36\">",
"      Combs SE, Hartmann C, Nikoghosyan A, et al. Carbon ion radiation therapy for high-risk meningiomas. Radiother Oncol 2010; 95:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44616/abstract/37\">",
"      Halasz LM, Bussi&egrave;re MR, Dennis ER, et al. Proton stereotactic radiosurgery for the treatment of benign meningiomas. Int J Radiat Oncol Biol Phys 2011; 81:1428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44616/abstract/38\">",
"      Morokoff AP, Zauberman J, Black PM. Surgery for convexity meningiomas. Neurosurgery 2008; 63:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44616/abstract/39\">",
"      Black PM, Villavicencio AT, Rhouddou C, Loeffler JS. Aggressive surgery and focal radiation in the management of meningiomas of the skull base: preservation of function with maintenance of local control. Acta Neurochir (Wien) 2001; 143:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44616/abstract/40\">",
"      Saeed P, Blank L, Selva D, et al. Primary radiotherapy in progressive optic nerve sheath meningiomas: a long-term follow-up study. Br J Ophthalmol 2010; 94:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44616/abstract/41\">",
"      Lesser RL, Knisely JP, Wang SL, et al. Long-term response to fractionated radiotherapy of presumed optic nerve sheath meningioma. Br J Ophthalmol 2010; 94:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44616/abstract/42\">",
"      Milker-Zabel S, Huber P, Schlegel W, et al. Fractionated stereotactic radiation therapy in the management of primary optic nerve sheath meningiomas. J Neurooncol 2009; 94:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44616/abstract/43\">",
"      Galloway TJ, Indelicato DJ, Amdur RJ, et al. Favorable outcomes of pediatric patients treated with radiotherapy to the central nervous system who develop radiation-induced meningiomas. Int J Radiat Oncol Biol Phys 2011; 79:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44616/abstract/44\">",
"      Kondziolka D, Kano H, Kanaan H, et al. Stereotactic radiosurgery for radiation-induced meningiomas. Neurosurgery 2009; 64:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44616/abstract/45\">",
"      Kalkanis SN, Qui&ntilde;ones-Hinojosa A, Buzney E, et al. Quality of life following surgery for intracranial meningiomas at Brigham and Women's Hospital: a study of 164 patients using a modification of the functional assessment of cancer therapy-brain questionnaire. J Neurooncol 2000; 48:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44616/abstract/46\">",
"      Dijkstra M, van Nieuwenhuizen D, Stalpers LJ, et al. Late neurocognitive sequelae in patients with WHO grade I meningioma. J Neurol Neurosurg Psychiatry 2009; 80:910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44616/abstract/47\">",
"      Chuang HC, Lee HC, Cho DY. Intracranial malignant meningioma with multiple spinal metastases--a case report and literature review: case report. Spine (Phila Pa 1976) 2006; 31:E1006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44616/abstract/48\">",
"      Chamberlain MC, Glantz MJ. Cerebrospinal fluid-disseminated meningioma. Cancer 2005; 103:1427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44616/abstract/49\">",
"      Slavin ML. Metastatic malignant meningioma. J Clin Neuroophthalmol 1989; 9:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44616/abstract/50\">",
"      Figueroa BE, Quint DJ, McKeever PE, Chandler WF. Extracranial metastatic meningioma. Br J Radiol 1999; 72:513.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5230 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-B007036579-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_36_44616=[""].join("\n");
var outline_f43_36_44616=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H444768437\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ACTIVE SURVEILLANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      SURGERY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Extent of resection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Surgical morbidity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Perioperative medical management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Seizures",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Cerebral edema",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Deep venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      RADIATION THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      RT after subtotal resection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      RT alone for nonresectable meningiomas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Dosage and toxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H444767541\">",
"      RT technical advances",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H444767548\">",
"      - Stereotactic radiosurgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H444767555\">",
"      - Stereotactic radiotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H444767562\">",
"      - Intensity-modulated RT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H444767569\">",
"      - Proton beam",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H444768026\">",
"      ONCOLOGIC AND FUNCTIONAL OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H444768033\">",
"      Convexity meningiomas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H444768040\">",
"      Skull base meningiomas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H444768047\">",
"      Optic nerve sheath meningiomas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H444768054\">",
"      Radiation-induced meningiomas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H444768061\">",
"      Quality of life",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SURVEILLANCE AFTER INITIAL TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      RECURRENT DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H444768437\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/5230\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/5230|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?28/44/29391\" title=\"figure 1\">",
"      Incidence rates of primary brain tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/5230|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?6/44/6862\" title=\"table 1\">",
"      CBTRUS incidence of primary CNS tumors",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/39/30327?source=related_link\">",
"      Anticoagulant and antiplatelet therapy in patients with brain tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/25/42389?source=related_link\">",
"      Atypical and malignant meningiomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/22/37226?source=related_link\">",
"      Complications of cranial irradiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/43/35514?source=related_link\">",
"      Hypercoagulable disorders associated with malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/59/2997?source=related_link\">",
"      Incidence of primary brain tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/55/32630?source=related_link\">",
"      Intensity-modulated radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/26/39335?source=related_link\">",
"      Management of vasogenic edema in patients with primary and metastatic brain tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/60/25540?source=related_link\">",
"      Meningioma: Clinical presentation and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/54/20328?source=related_link\">",
"      Meningioma: Epidemiology, risk factors, and pathology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/39/40570?source=related_link\">",
"      Overview of the management of epilepsy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/12/1224?source=related_link\">",
"      Pathogenesis of the hypercoagulable state associated with malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?5/15/5362?source=related_link\">",
"      Patient information: Meningioma (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/61/43994?source=related_link\">",
"      Pharmacology of antiepileptic drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/52/41802?source=related_link\">",
"      Prevention of venous thromboembolic disease in surgical patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/16/18697?source=related_link\">",
"      Seizures in patients with primary and metastatic brain tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/5/32855?source=related_link\">",
"      Stereotactic cranial radiosurgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/2/4133?source=related_link\">",
"      Systemic treatment of recurrent meningioma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f43_36_44617="Treatment of HIV-associated lipodystrophy";
var content_f43_36_44617=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of HIV-associated lipodystrophy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/36/44617/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/36/44617/contributors\">",
"     Marshall J Glesby, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/36/44617/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/36/44617/contributors\">",
"     John G Bartlett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/36/44617/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/36/44617/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?43/36/44617/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 5, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term HIV-associated lipodystrophy typically refers to changes in fat distribution that are often associated with metabolic abnormalities, including dyslipidemia and insulin resistance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44617/abstract/1\">",
"     1",
"    </a>",
"    ]. Specifically, patients with lipoatrophy have loss of subcutaneous fat, most noticeably in the limbs, face,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    buttocks areas. Patients with fat accumulation have gain of visceral fat in the abdomen and may have dorsocervical fat pad enlargement (buffalo hump) and breast enlargement.",
"   </p>",
"   <p>",
"    Patients may present with lipoatrophy, fat accumulation, or a combination of the two [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44617/abstract/2\">",
"     2",
"    </a>",
"    ]. Since potential management differs depending on the nature of the change in fat, lipoatrophy and fat accumulation will be discussed separately after a general consideration of the rationale for treating these disorders.",
"   </p>",
"   <p>",
"    The treatment of HIV-associated lipodystrophy will be reviewed here. The epidemiology, clinical manifestations, and diagnosis of lipodystrophy are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/43/26298?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of HIV-associated lipodystrophy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RATIONALE FOR TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are multiple reasons to consider treating HIV-associated lipodystrophy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients are often distressed by the physical changes in their appearance, especially if they develop facial lipoatrophy. These morphologic abnormalities can have a significant impact on self-esteem [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/36/44617/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The presence of lipodystrophy raises concern, for some patients, that their HIV status will be obvious to others [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/36/44617/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Lipodystrophy, or fear of developing it, may impact adherence to antiretroviral therapy or the willingness to initiate such therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/36/44617/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Some patients with increased neck fat report restricted neck movement and women with breast enlargement may have chronic back pain. Amelioration of lipodystrophy may improve quality of life.",
"     </li>",
"     <li>",
"      The metabolic derangements associated with lipodystrophy may predispose patients to accelerated atherosclerosis and diabetes mellitus. Therapeutic interventions to address HIV-associated lipodystrophy have the potential to favorably affect metabolic parameters and ultimately reduce the risk of atherosclerosis and diabetes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     FAT ATROPHY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Therapeutic approaches to fat atrophy (lipoatrophy) include medical management and surgical interventions (",
"    <a class=\"graphic graphic_table graphicRef53050 \" href=\"mobipreview.htm?18/40/19083\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Switching antiretrovirals",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data from epidemiological studies and clinical trials suggest that use of thymidine analogue nucleoside reverse transcriptase inhibitors (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/45/43734?source=see_link\">",
"     stavudine",
"    </a>",
"    and, to a lesser extent,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    ) is strongly associated with the development of lipoatrophy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44617/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. Observational data also suggest that use of protease inhibitors (PIs) with nucleoside reverse transcriptase inhibitors may accelerate the rate of fat loss [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44617/abstract/9\">",
"     9",
"    </a>",
"    ], although in one randomized trial, limb fat loss was more common in subjects receiving NRTIs plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    compared to NRTIs plus the PI",
"    <span class=\"nowrap\">",
"     lopinavir/",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"      ritonavir",
"     </a>",
"     &nbsp;[",
"     <a class=\"abstract\" href=\"mobipreview.htm?43/36/44617/abstract/10\">",
"      10",
"     </a>",
"     ].",
"    </span>",
"   </p>",
"   <p>",
"    Consequently,",
"    a number of studies have examined the effects of switching from a presumed offending drug to another one not thought to cause lipoatrophy. Switching from a protease inhibitor to a non-nucleoside reverse transcriptase inhibitor (NNRTI) or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/63/31734?source=see_link\">",
"     abacavir",
"    </a>",
"    has not resulted in improvement in lipoatrophy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44617/abstract/11-14\">",
"     11-14",
"    </a>",
"    ]. In contrast, switching from thymidine analogues (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/45/43734?source=see_link\">",
"     stavudine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    ) to alternative nucleoside analog agents has resulted in modest gains in limb fat [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44617/abstract/15-17\">",
"     15-17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a randomized study of 111 patients with moderate to severe lipoatrophy (85 on",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/45/43734?source=see_link\">",
"       stavudine",
"      </a>",
"      and 26 on",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/28/24008?source=see_link\">",
"       zidovudine",
"      </a>",
"      ), patients were randomly assigned to either switch their thymidine analogue therapy to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?30/63/31734?source=see_link\">",
"       abacavir",
"      </a>",
"      or to continue treatment without change. At 24 weeks, patients who switched to abacavir had modest increases in limb fat compared with those who continued thymidine analogue therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/36/44617/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a longer-term extension study, those switching to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?30/63/31734?source=see_link\">",
"       abacavir",
"      </a>",
"      had a 36 percent increase in limb fat at two years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/36/44617/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a randomized study of 110 patients with moderate to severe lipoatrophy (71 on",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/45/43734?source=see_link\">",
"       stavudine",
"      </a>",
"      and 32 on",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/28/24008?source=see_link\">",
"       zidovudine",
"      </a>",
"      ), patients were randomly assigned to switch their thymidine analogue therapy to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?30/63/31734?source=see_link\">",
"       abacavir",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"       tenofovir",
"      </a>",
"      . At 48 weeks, patients in both groups had similar, modest increases in limb fat [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/36/44617/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These data suggest that switching from a thymidine analogue NRTI (ie,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/45/43734?source=see_link\">",
"     stavudine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    ) to an alternative agent, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/63/31734?source=see_link\">",
"     abacavir",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    , is a reasonable strategy to reverse, or slow progression of, lipoatrophy. Gains in fat have been modest over the short-term, and patients should be advised not to expect dramatic changes in appearance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44617/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. Importantly, an individual's prior antiretroviral treatment history and resistance profile must also be taken into account prior to changing antiretrovirals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44617/abstract/21\">",
"     21",
"    </a>",
"    ]. Recent observational data suggesting that abacavir use may be associated with increased risk of myocardial infarction, especially in patients with multiple cardiovascular risk factors, and might also be factored into the choice of drugs to which a patient is switched [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44617/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/18/3370?source=see_link\">",
"     \"Considerations prior to initiating antiretroviral therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Another strategy involves switching to a PI-containing, nucleoside-sparing regimen. This approach was evaluated in 62 patients with advanced HIV, but not necessarily lipoatrophy, who were switched from their initial successful ART regimen to one including",
"    <span class=\"nowrap\">",
"     lopinavir/",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"      ritonavir",
"     </a>",
"    </span>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    versus two nucleoside analogues and efavirenz (ACTG 5125) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44617/abstract/24\">",
"     24",
"    </a>",
"    ]. Although limb fat significantly increased in the nucleoside analog-sparing arm at 48 weeks, this was also accompanied by a significant increase in triglycerides and total cholesterol as well.",
"   </p>",
"   <p>",
"    Switching from an older generation PI to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/31/506?source=see_link\">",
"     atazanavir",
"    </a>",
"    has also been evaluated. In a trial of 201 HIV patients with abdominal fat accumulation and viral suppression on a regimen containing a twice-daily",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    -boosted protease inhibitor, half of whom were taking thymidine analogues, there was a trend towards less limb fat loss at 48 weeks among those who were randomly assigned to switch to a regimen containing ritonavir-boosted atazanavir (0.9 versus -3.6 percent change in patients remaining on their original regimen) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44617/abstract/25\">",
"     25",
"    </a>",
"    ]. This difference, however, was not statistically significant. There was no difference in abdominal adiposity between the two groups, either. However, switching to atazanavir favorably affected lipid profiles, as seen in other studies, and thus may be warranted for reasons other than effects on lipoatrophy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/3/49?source=see_link&amp;anchor=H8#H8\">",
"     \"Management of dyslipidemia and cardiovascular risk in the HIV-infected patient\", section on 'Role of antiretroviral therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Thiazolidinediones",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thiazolidinediones are insulin-sensitizing agents used in the treatment of diabetes. In congenital forms of lipodystrophy not associated with HIV, treatment with a thiazolidinedione decreased visceral fat and improved insulin sensitivity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44617/abstract/26\">",
"     26",
"    </a>",
"    ]. These data suggested that thiazolidinedione drugs could have a role in managing HIV-associated lipodystrophy as well.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Rosiglitazone",
"    </span>",
"    &nbsp;&mdash;&nbsp;To date, four randomized, placebo-controlled trials of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/26/2472?source=see_link\">",
"     rosiglitazone",
"    </a>",
"    for HIV-associated lipoatrophy have been published; three of these studies did not show any improvement in lipoatrophy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44617/abstract/27-30\">",
"     27-30",
"    </a>",
"    ]. In the largest study of 108 patients with lipoatrophy, documented by dual x-ray energy absorptiometry (DEXA) scanning, there were no differences in the change in limb fat between the treatment and placebo arms after 48 weeks of follow-up [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44617/abstract/27\">",
"     27",
"    </a>",
"    ]. In a similar study of 30 patients, rosiglitazone did not affect subcutaneous or intra-abdominal fat, although liver fat was reduced [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44617/abstract/28\">",
"     28",
"    </a>",
"    ]. In contrast, rosiglitazone led to a 24 percent increase in subcutaneous leg fat area in a study of 28 patients with lipoatrophy and hyperinsulinemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44617/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Differences in outcome in these various studies may be related in part to varying use of thymidine NRTIs in the study populations. A substudy of one of the randomized placebo-controlled trials noted above [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44617/abstract/27\">",
"     27",
"    </a>",
"    ] assessed serial fat biopsies for mitochondrial gene expression, DNA content, and mRNA expression of peroxisome proliferator-activated receptor gamma (PPARG), an important regulator of adipocyte differentiation and function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44617/abstract/31\">",
"     31",
"    </a>",
"    ]. Patients who were receiving thymidine NRTIs had lower mitochondrial RNA expression and DNA content at baseline compared to other patients. Exposure to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/26/2472?source=see_link\">",
"     rosiglitazone",
"    </a>",
"    , a PPARG antagonist, did not affect PPARG expression at week 2 or week 48 in those patients currently taking thymidine NRTIs. In patients who were not taking thymidine NRTIs, improved PPARG expression was associated with increases in limb fat. These data suggest a direct link between mitochondrial toxicity and PPARG expression and may explain the limited therapeutic benefit of thiazolidinediones in the face of ongoing thymidine analogue use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44617/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A subsequent randomized, double-blind trial was performed to assess the potential benefit of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/26/2472?source=see_link\">",
"     rosiglitazone",
"    </a>",
"    in 71 patients who were taking thymidine-sparing regimens a minimum of 24 weeks prior to enrollment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44617/abstract/33\">",
"     33",
"    </a>",
"    ]. Patients taking rosiglitazone had significant improvements in limb fat compared with those in the placebo group. Lower insulin levels were also seen in the subset of patients who had evidence of insulin resistance at baseline.",
"   </p>",
"   <p>",
"    Although",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/26/2472?source=see_link\">",
"     rosiglitazone",
"    </a>",
"    has been associated with improvements in insulin sensitivity, cholesterol levels have also increased. A meta-analysis has raised concerns about increased risk of myocardial infarction and cardiovascular death in diabetics treated with rosiglitazone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44617/abstract/34\">",
"     34",
"    </a>",
"    ], though a large, randomized clinical trial designed to evaluate the cardiovascular safety of this drug was inconclusive [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44617/abstract/35\">",
"     35",
"    </a>",
"    ]. The relevance of this controversy to nondiabetic patients is uncertain. In September 2010 the Food and Drug Administration announced that it will restrict access to rosiglitazone through use of a Risk Evaluation and Mitigation Strategy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44617/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Pioglitazone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increases in both leg and trunk fat have been demonstrated in an uncontrolled trial of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/28/43463?source=see_link\">",
"     pioglitazone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44617/abstract/37\">",
"     37",
"    </a>",
"    ]. In contrast to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/26/2472?source=see_link\">",
"     rosiglitazone",
"    </a>",
"    , pioglitazone appears to decrease the risk of myocardial infarction in diabetics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44617/abstract/38\">",
"     38",
"    </a>",
"    ]. Although less data exist on pioglitazone in HIV-infected patients, one placebo-controlled trial of 130 such patients with lipoatrophy showed promising results. Overall, limb fat increased by 0.38 kg in the pioglitazone arm and increased by 0.05 kg in the placebo arm at 48 weeks (p = 0.051) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44617/abstract/39\">",
"     39",
"    </a>",
"    ]. The difference between arms was greater and statistically significant in a pre-planned subgroup analysis of patients who were not taking",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/45/43734?source=see_link\">",
"     stavudine",
"    </a>",
"    , whereas those on stavudine had no benefit. Of note, pioglitazone has been associated with increased risk of bladder cancer in patients with diabetes mellitus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44617/abstract/40\">",
"     40",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/50/21290?source=see_link&amp;anchor=H12774482#H12774482\">",
"     \"Thiazolidinediones in the treatment of diabetes mellitus\", section on 'Bladder cancer'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Taken together, thiazolidinedione drugs are of possible benefit in the treatment of lipoatrophy but their use remains investigational. Clinicians might consider a therapeutic trial of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/28/43463?source=see_link\">",
"     pioglitazone",
"    </a>",
"    in patients with lipoatrophy who have evidence of insulin resistance (eg, elevated fasting glucose or impaired glucose tolerance on a standard oral glucose tolerance test) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44617/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The available thiazolidinediones are related structurally to troglitazone, which was removed from the market due to idiosyncratic hepatotoxicity, including liver failure. Consequently, clinicians should monitor liver enzymes closely in patients receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/28/43463?source=see_link\">",
"     pioglitazone",
"    </a>",
"    (eg, at one month after initiation), then every two months for the first year, and periodically thereafter. Patients should be advised to report immediately any potential signs of bladder cancer, such as hematuria.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Uridine",
"    </span>",
"    &nbsp;&mdash;&nbsp;In vitro data suggest that uridine, a pyrimidine nucleoside, can protect adipocytes from the adverse effects of thymidine analogues [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44617/abstract/42\">",
"     42",
"    </a>",
"    ]. NucleomaxX&reg;, a sugar cane-derived dietary supplement, increases uridine levels; a small, randomized trial in patients receiving thymidine analogues suggested that NucleomaxX&reg; favorably affected limb fat [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44617/abstract/43\">",
"     43",
"    </a>",
"    ]. However, a subsequent multicenter clinical trial of 165 participants found that uridine supplementation did not improve limb fat after 48 weeks of treatment compared to placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44617/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Leptin",
"    </span>",
"    &nbsp;&mdash;&nbsp;A pilot crossover study evaluated the efficacy of recombinant methionyl leptin supplementation in seven HIV-infected men with leptin deficiency and lipoatrophy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44617/abstract/45\">",
"     45",
"    </a>",
"    ]. Compared with placebo, two months of leptin therapy improved fasting insulin levels, insulin resistance, and high-density lipoprotein levels. Another study in eight hypoleptinemic patients demonstrated similar findings in addition to decrease in visceral fat [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44617/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Surgical approaches",
"    </span>",
"    &nbsp;&mdash;&nbsp;Facial lipoatrophy is characterized by loss of the buccal",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    temporal fat pads, leading to facial skeletonization with concave cheeks, prominent nasolabial folds, periorbital hollowing, and visible facial musculature [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44617/abstract/47\">",
"     47",
"    </a>",
"    ]. Facial lipoatrophy is stigmatizing and can lead to low self-esteem and depressive symptoms. Plastic surgery is the main therapy for severe facial lipoatrophy; autologous fat transplantation or more commonly, injections of biodegradable or nonbiodegradable gel fillers can be performed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6175174\">",
"    <span class=\"h3\">",
"     Gel fillers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plastic surgeons, dermatologists, and others with specific training have treated facial lipoatrophy with various injectable fillers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44617/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. Permanent fillers are synthetic materials that are designed to permanently fill in the space vacated by loss of facial fat. Permanent fillers, none of which are approved by the FDA for dermal augmentation, include purified silicone oil, polymethylmethacrylate, polyalkylamide, and polytetrafluoroethylene [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44617/abstract/50\">",
"     50",
"    </a>",
"    ]. In general, use of permanent fillers is less desirable than temporary fillers due to potential worsening or improvement in facial lipoatrophy as a result of continuing or changing antiretroviral therapy, which may result in undesirable cosmetic effects such as sagging of skin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44617/abstract/51\">",
"     51",
"    </a>",
"    ]. Furthermore, infectious complications have been reported with some permanent fillers. In a review of 267 patients who received a polyalkylimide filler (Bio-Alcamid) for HIV-associated facial lipoatrophy, 56 patients (19 percent) developed an implant-associated infection at a median of 32 months following implantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44617/abstract/52\">",
"     52",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/26/26024?source=see_link\">",
"     \"Injectable soft tissue fillers: Permanent agents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast to permanent fillers, temporary fillers are reinjected at regular intervals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44617/abstract/50\">",
"     50",
"    </a>",
"    ]. To date, two fillers are FDA approved specifically for HIV-associated lipoatrophy.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/21/13651?source=see_link\">",
"     Poly-L-lactic acid",
"    </a>",
"    (PLLA or Sculptra&trade;) is a biodegradable, biocompatible, immunologically inert substance that has been used in dissolvable sutures and dental implants. This product consists of microspheres of poly-L-lactic acid that are 40 to 60 microns in diameter that initially expand tissue after injection by purely mechanical means but gradually biodegrade and stimulate collagen formation as a foreign body [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44617/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. Only small studies of PLLA have been performed to date with limited follow-up [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44617/abstract/55-57\">",
"     55-57",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In an open-label study in 50 patients with severe facial lipoatrophy, the mean increase in dermal thickness assessed by ultrasound was approximately 7 mm at 96 weeks [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/36/44617/abstract/55\">",
"       55",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another study, 101 patients were randomly assigned to either immediate or deferred therapy with PLLA [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/36/44617/abstract/56\">",
"       56",
"      </a>",
"      ]. Although there were no significant changes in facial tissue volume between the immediate and deferred therapy groups (as assessed by spiral CT), subjective measures of severity were improved in 90 percent of patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A typical treatment course of PLLA is three to six injections separated by two or more weeks. Local adverse effects lasting several days, including bruising and edema, are common. Up to half of patients develop subcutaneous papules at the injection site a median of seven months after the initial injection, and one quarter to one half of these papules resolve spontaneously [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44617/abstract/54,58\">",
"     54,58",
"    </a>",
"    ]. Although there are some encouraging reports regarding this technique, reimbursement issues preclude their use for most patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/23/23930?source=see_link&amp;anchor=H44882103#H44882103\">",
"     \"Injectable soft tissue fillers: Semipermanent agents\", section on 'Poly-L-lactic acid (Sculptra&reg;)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Calcium hydroxylapatite (Radiesse&trade;) is also FDA approved for HIV-associated facial lipoatrophy. The hydroxyapatite microspheres serve as scaffolding for collagen growth. In an open-label study in 100 patients with facial lipoatrophy, 100 percent met the primary efficacy endpoint of improvement on the Global Aesthetic Improvement Scale at three months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44617/abstract/59\">",
"     59",
"    </a>",
"    ]. The subjective improvement was sustained through 12 months of follow-up, and skin thickness increased significantly by a mean of 2.3 mm at 12 months. Local adverse effects were generally mild and short-lived and included ecchymosis, edema, erythema, pain, and pruritus. Concerns about cost and reimbursement are similar to PLLA. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/23/23930?source=see_link&amp;anchor=H44882068#H44882068\">",
"     \"Injectable soft tissue fillers: Semipermanent agents\", section on 'Calcium hydroxylapatite (Radiesse&reg;)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Anecdotal experiences with other temporary fillers, none of which are FDA approved for the indication of facial lipoatrophy, include bovine or human collagen, hyaluronic acid, and autologous fat [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44617/abstract/50\">",
"     50",
"    </a>",
"    ]. Use of autologous fat implantation is often limited by the lack of suitable donor sites in patients with extensive lipoatrophy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6175181\">",
"    <span class=\"h3\">",
"     Autologous fat transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autologous fat transplantation involves harvesting of a small intact lump of fatty tissue from the abdomen, cervicodorsal area, or elsewhere, that can be processed into small fat &ldquo;parcels&rdquo; that are injected by a syringe with local anesthesia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44617/abstract/47\">",
"     47",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/26/26024?source=see_link&amp;anchor=H875327#H875327\">",
"     \"Injectable soft tissue fillers: Permanent agents\", section on 'Autologous fat'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recognition of the association between thymidine analogue use (particularly",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/45/43734?source=see_link\">",
"     stavudine",
"    </a>",
"    ) and lipoatrophy has led to preferential use of other NRTIs for initial therapy of HIV.",
"   </p>",
"   <p>",
"    Data from a randomized, double-blind comparison in antiretroviral-naive patients of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/45/43734?source=see_link\">",
"     stavudine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    , both in combination with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    , provide supporting data for this approach [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44617/abstract/60\">",
"     60",
"    </a>",
"    ]. After 133 weeks of therapy, the patients randomly assigned to tenofovir demonstrated normal limb fat compared with a significant decline in lower limb fat mass in nearly 50 percent of patients receiving stavudine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44617/abstract/60\">",
"     60",
"    </a>",
"    ]. Although baseline assessments were not done, these data strongly suggest that use of tenofovir is not associated with lipoatrophy.",
"   </p>",
"   <p>",
"    Similar findings were noted in a 48 week open-label study of 517 antiretroviral therapy-naive patients who were randomly assigned to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/52/1863?source=see_link\">",
"     tenofovir-emtricitabine",
"    </a>",
"    compared with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/56/901?source=see_link\">",
"     zidovudine-lamivudine",
"    </a>",
"    , both in combination with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44617/abstract/61\">",
"     61",
"    </a>",
"    ]. The primary endpoint of the study was virologic efficacy; however, in a subset analysis of 49 patients in the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    -",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    arm and 51 patients in the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    -emtricitabine arm who underwent dual-energy x-ray absorptiometry (DEXA), total limb fat was significantly less in the former group.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     FAT DEPOSITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Potential interventions for fat deposition (lipodeposition) include exercise, medical therapy, and surgical interventions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Exercise",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exercise is a safe and potentially useful intervention for patients with abdominal fat accumulation, though efficacy data are quite limited [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44617/abstract/62\">",
"     62",
"    </a>",
"    ]. In a study of 17 HIV-infected patients, 15 of whom had fat accumulation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    lipoatrophy, an individualized, supervised, aerobic training program led to preferential loss of visceral fat and improvements in total cholesterol, triglycerides, and HDL-C at four months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44617/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Metformin",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a randomized, placebo-controlled trial of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    500 mg twice daily for three months in HIV-infected patients with central obesity and hyperinsulinemia, metformin improved insulin sensitivity, tended to reduce both visceral and subcutaneous abdominal fat, and improved markers of impaired fibrinolysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44617/abstract/64,65\">",
"     64,65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a randomized comparison of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    with or without a supervised aerobic and resistance training exercise program, patients in the exercise plus metformin arm had statistically significant reductions in both visceral and subcutaneous abdominal fat and greater improvements in specific cardiovascular risk markers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44617/abstract/66\">",
"     66",
"    </a>",
"    ]. In this small study (n=37), two patients were withdrawn due to asymptomatic elevations in lactate and two due to liver enzyme elevations.",
"   </p>",
"   <p>",
"    Based on the available data,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    cannot be recommended to reduce truncal fat in non-diabetic patients, as the",
"    <span class=\"nowrap\">",
"     risk/benefit",
"    </span>",
"    ratio is not well defined. Metformin is a reasonable treatment option for diabetic patients, especially those with increased truncal fat who have intact renal and hepatic function. Metformin should be avoided in patients who predominantly have lipoatrophy of moderate to severe severity since it may further reduce subcutaneous fat [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44617/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Growth hormone and related drugs",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Recombinant human growth hormone",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/54/12137?source=see_link\">",
"     Recombinant human growth hormone",
"    </a>",
"    (rhGH) is known to be lipolytic; patients with AIDS-related wasting treated with supraphysiologic doses of rhGH (Serostim&reg;) lost body fat while gaining lean body mass [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44617/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This observation provided the rationale for studying the efficacy of rhGH in the treatment of patients with fat accumulation initially in pilot studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44617/abstract/69-71\">",
"     69-71",
"    </a>",
"    ] and ultimately in randomized, placebo-controlled trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44617/abstract/72,73\">",
"     72,73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a phase III trial, 325 HIV-infected adults with elevated waist circumference and waist:hip ratios were randomized to receive rhGH induction at 4 mg daily or placebo for 12 weeks, all by subcutaneous injection [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/36/44617/abstract/73\">",
"       73",
"      </a>",
"      ]. In the rhGH arm, visceral abdominal fat was reduced preferentially relative to subcutaneous abdominal fat, with reductions of 20 percent and 7 percent, respectively. rhGH-induced changes in fat were associated with reductions in low density lipoprotein cholesterol and increases in high density lipoprotein cholesterol.",
"      <br/>",
"      <br/>",
"      In the second phase of this study, patients initially taking rhGH were randomized to maintenance therapy with 2 mg of rhGH on alternate days or placebo for 24 weeks. Among those who lost visceral fat in the initial 12 weeks of the study, 40 percent regained over 50 percent of the fat that was lost, which was significantly less than the placebo arm and met the predetermined endpoint for efficacy of maintenance therapy.",
"     </li>",
"     <li>",
"      In a randomized, double-blind, placebo-controlled trial of 56 patients with abdominal fat accumulation and reduced GH secretion, patients were randomly assigned to receive either low-dose subcutaneous GH or matching placebo [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/36/44617/abstract/74\">",
"       74",
"      </a>",
"      ]. Main outcome measures were a change in body composition assessed by CT and DEXA. After 18 months of treatment, receipt of GH resulted in significantly reduced visceral fat and truncal obesity, triglycerides, and diastolic blood pressure; however, two-hour glucose levels on glucose tolerance testing were increased. In an extension phase, patients who were originally on GH received placebo for an additional 18 months and had rapid rebound of visceral fat to a level above initial baseline values [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/36/44617/abstract/75\">",
"       75",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The major side effects of rhGH are fluid retention, arthralgias, myalgias, and, less commonly, carpal tunnel syndrome and diabetes mellitus. Of note, studies of rhGH for increased truncal fat have generally excluded patients with impaired fasting glucose and impaired glucose tolerance on a standard, 75 gram 2-hour oral glucose tolerance test, since these patients may be at increased risk of developing rhGH-induced hyperglycemia and diabetes. While maintenance therapy with rhGH after an induction phase was superior to placebo in the phase III trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44617/abstract/73\">",
"     73",
"    </a>",
"    ], the optimal strategy for maintaining visceral fat reduction that may be achieved from rhGH induction is uncertain. rhGH is not currently indicated for the treatment of HIV-associated truncal obesity and its clinical development for this indication appears to be on hold.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Recombinant human growth hormone releasing hormone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Growth hormone releasing hormone (GHRH) is produced in the hypothalamus and stimulates growth hormone secretion by the pituitary gland. Growth hormone induces hepatic synthesis of insulin-like growth factor 1 (IGF-1), which mediates most of the peripheral actions of growth hormone. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/7/3192?source=see_link\">",
"     \"Physiology of insulin-like growth factor I\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    After preliminary data with GHRH suggested clinical benefit without affecting glycemic control, two large clinical trials were designed to evaluate the efficacy and safety of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/29/32212?source=see_link\">",
"     tesamorelin",
"    </a>",
"    , an analog of GHRH. &nbsp;Evidence of benefit without affecting glycemic control in initial studies of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/54/12137?source=see_link\">",
"     recombinant human growth hormone",
"    </a>",
"    releasing hormone (eg, sermorelin acetate) or an analog (tesamorelin; Egrifta) provided the rationale for two large clinical trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44617/abstract/76,77\">",
"     76,77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The first trial included 412 patients on ART who were randomly assigned in a ratio of 2:1 to receive either 2 mg of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/29/32212?source=see_link\">",
"     tesamorelin",
"    </a>",
"    or placebo for 26 weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44617/abstract/78\">",
"     78",
"    </a>",
"    ]. Eligible patients had excessive accumulation of abdominal fat as measured by gender-specific waist circumference and waist-to-hip ratios. The study results were significant for the following findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Visceral adipose tissue (VAT) decreased by 15 percent in the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/29/32212?source=see_link\">",
"       tesamorelin",
"      </a>",
"      group and increased by 5 percent in the placebo group.",
"     </li>",
"     <li>",
"      Lipid profiles also improved in the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/29/32212?source=see_link\">",
"       tesamorelin",
"      </a>",
"      arm; triglyceride levels decreased by 50",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (0.57",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      and the ratio of total cholesterol to HDL cholesterol decreased by approximately one-third.",
"     </li>",
"     <li>",
"      There was no worsening of glucose tolerance as seen in the trials of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/54/12137?source=see_link\">",
"       recombinant human growth hormone",
"      </a>",
"      described above.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Adverse events were similar in both groups, although",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/29/32212?source=see_link\">",
"     tesamorelin",
"    </a>",
"    therapy was associated with a higher rate of discontinuation due to adverse events. Six (2.2 percent) patients taking tesamorelin developed urticaria, one of which had transient systemic symptoms.",
"   </p>",
"   <p>",
"    At 26 weeks, patients originally on",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/29/32212?source=see_link\">",
"     tesamorelin",
"    </a>",
"    were re-randomized to 2 mg of tesamorelin or placebo, whereas patients originally on placebo were switched to tesamorelin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44617/abstract/79\">",
"     79",
"    </a>",
"    ]. The change in VAT was sustained over 52 weeks of treatment; however, upon discontinuation of drug, VAT reaccumulated. A significant proportion of patients also developed antibodies to tesamorelin, which did not appear to be neutralizing. Long-term safety data are not yet available.",
"   </p>",
"   <p>",
"    The second trial randomized 404 patients to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/29/32212?source=see_link\">",
"     tesamorelin",
"    </a>",
"    2 mg daily or placebo for six months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44617/abstract/80\">",
"     80",
"    </a>",
"    ]. &nbsp;In an extension phase, 265 patients were re-randomized to continue tesamorelin or switch to placebo for an additional six months. Patients who received tesamorelin for the entire study period of 12 months had an 18 percent reduction in VAT whereas those who switched to placebo had reaccumulation to baseline levels. A pooled analysis of both phase III trials noted a small (2.9 percent) but statistically significant increase in hemoglobin A1C at week 26 in subjects receiving tesamorelin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44617/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based on these data, the FDA approved",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/29/32212?source=see_link\">",
"     tesamorelin",
"    </a>",
"    for the treatment of excess abdominal fat in HIV-infected patients in November 2010. Tesamorelin is a reasonable treatment option for HIV-infected patients without active malignancy who are distressed by moderate to severe abdominal fat accumulation. Therapy should not be continued beyond six months if there is no treatment response, assessed by a decrease in waist circumference.",
"   </p>",
"   <p>",
"    The rapid re-accumulation of fat after treatment discontinuation, and the lack of long-term safety data, present challenges for defining the optimal use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/29/32212?source=see_link\">",
"     tesamorelin",
"    </a>",
"    . The FDA is requiring a long-term observational safety study of at least 10 years&rsquo; duration comparing patients with HIV-associated lipodystrophy and excess abdominal fat treated with tesamorelin, with a similar group of untreated patients. Although safety data do not exist for treatment longer than one year&rsquo;s duration, physicians may consider using this agent for longer periods of time, in accordance with the prescribing information; treatment can be continued if the patient continues to show clinical benefit and has no significant adverse events.",
"   </p>",
"   <p>",
"    In the phase III trials of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/29/32212?source=see_link\">",
"     tesamorelin",
"    </a>",
"    , approximately half of the subjects developed IGF-1 elevations. Given epidemiological associations between IGF-1 levels and malignancy risk in the general population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44617/abstract/82,83\">",
"     82,83",
"    </a>",
"    ] and the increased risk of specific malignancies in HIV-infected patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44617/abstract/84\">",
"     84",
"    </a>",
"    ], there are theoretical long-term safety concerns about prolonged elevations of IGF-1 levels induced by tesamorelin.",
"   </p>",
"   <p>",
"    There are no data on the roles of drug discontinuation, dose reduction, or intermittent dosing of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/29/32212?source=see_link\">",
"     tesamorelin",
"    </a>",
"    in the setting of IGF-1 elevations. There are also no firm guidelines on how often to monitor IGF-1 levels.",
"   </p>",
"   <p>",
"    We suggest that physicians using",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/29/32212?source=see_link\">",
"     tesamorelin",
"    </a>",
"    should monitor insulin-like growth factor (IGF-I) at least every six months and should aim to keep IGF-I within the normal range of the assay used. Clinicians should consider stopping tesamorelin if IGF-1 elevations persist.",
"   </p>",
"   <p>",
"    Due to the potential for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/29/32212?source=see_link\">",
"     tesamorelin",
"    </a>",
"    to adversely affect glucose tolerance, we recommend obtaining a hemoglobin A1c at baseline and every three to four months during therapy to screen for new onset diabetes and to monitor glycemic control in patients with pre-existing diabetes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Thiazolidinediones",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although thiazolidinediones reduce visceral adipose tissue volume in diabetics without known HIV infection, controlled studies to date have generally not demonstrated such favorable effects in HIV-infected patients, including those with insulin resistance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Surgical approaches",
"    </span>",
"    &nbsp;&mdash;&nbsp;Suction assisted lipectomy (liposuction) has been used successfully to manage dorsocervical fat accumulation, though some patients have recurrent fat accumulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44617/abstract/85,86\">",
"     85,86",
"    </a>",
"    ]. Anecdotally, reduction mammoplasty has been successful for women with breast enlargement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44617/abstract/87\">",
"     87",
"    </a>",
"    ]. The visceral nature of abdominal fat accumulation precludes surgical management.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unlike with lipoatrophy, clear associations between fat accumulation and specific antiretroviral agents are less apparent. It is not clear if use of protease inhibitor-sparing antiretroviral regimens or the protease inhibitor",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/31/506?source=see_link\">",
"     atazanavir",
"    </a>",
"    , which does not adversely affect lipids and insulin sensitivity, will prevent fat accumulation. In a randomized double-blind comparison of atazanavir with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    , both in combination with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    , similar modest gains in visceral abdominal fat volume were seen in both arms at 48 weeks of therapy, perhaps due to improvements in general health [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/36/44617/abstract/88\">",
"     88",
"    </a>",
"    ]. Other than encouraging exercise and monitoring weight, no specific prevention measures can be recommended at this time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fat atrophy (lipoatrophy) and fat accumulation (lipodeposition) appear to be separate processes that should be addressed independently in a given patient, if they co-exist. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are many rationales to treat lipodystrophy in the HIV-infected patient. The presence of lipodystrophy raises concern, for some patients, that their HIV status will be obvious to others and may indirectly affect adherence to antiretroviral medications. The metabolic derangements associated with lipodystrophy may also predispose patients to accelerated atherosclerosis and diabetes mellitus. Therapeutic interventions to address HIV-associated lipodystrophy have the potential to favorably affect metabolic parameters and ultimately reduce the risk of atherosclerosis and diabetes. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Rationale for treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with lipoatrophy who are on",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/45/43734?source=see_link\">",
"       stavudine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/28/24008?source=see_link\">",
"       zidovudine",
"      </a>",
"      , we suggest switching to an alternative agent, such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"       tenofovir",
"      </a>",
"      or possibly",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?30/63/31734?source=see_link\">",
"       abacavir",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_4?title=Grade 2A\">",
"       Grade 2A",
"      </a>",
"      ). The presence of pre-existing HIV drug resistance and the patient's treatment history must be considered prior to changing antiretrovirals to reduce the risk of virologic failure.",
"     </li>",
"     <li>",
"      In patients with lipoatrophy who have coexisting hyperinsulinemia or impaired glucose tolerance, we suggest a therapeutic trial of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/28/43463?source=see_link\">",
"       pioglitazone",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Patients should have careful monitoring of liver enzymes. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Fat atrophy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with severe facial lipoatrophy, who would like to undergo cosmetic remodeling, we suggest use of injectable temporary fillers rather than permanent fillers, and consultation with a dermatologist or plastic surgeon with expertise in this area (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Surgical approaches'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest standard methods of weight reduction, such as aerobic exercise training, in patients with fat deposition (lipodeposition) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). In patients with concomitant diabetes, we suggest aerobic exercise training with preferential use of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"       metformin",
"      </a>",
"      for glycemic control (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Metformin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/29/32212?source=see_link\">",
"       Tesamorelin",
"      </a>",
"      , a growth hormone releasing factor analogue administered by subcutaneous injection, has been shown to be efficacious in reducing visceral fat accumulation in clinical trials. We recommend tesamorelin for the treatment of excess abdominal fat in HIV-infected patients who have not responded to exercise and dietary interventions and who are distressed by their cosmetic appearance. Patients should be monitored for adverse events and for the development of hyperglycemia. &nbsp; &nbsp;",
"     </li>",
"     <li>",
"      Patients should be counseled that fat generally re-accumulates back to baseline after",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/29/32212?source=see_link\">",
"       tesamorelin",
"      </a>",
"      discontinuation, long-term safety data are lacking, and the optimal duration of treatment remains unknown. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Growth hormone and related drugs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with lipomas that are disfiguring or in uncomfortable locations may benefit from suction-assisted lipectomy (liposuction). Patients should be counseled that recurrences can sometimes be seen. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Surgical approaches'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44617/abstract/1\">",
"      Wohl DA, McComsey G, Tebas P, et al. Current concepts in the diagnosis and management of metabolic complications of HIV infection and its therapy. Clin Infect Dis 2006; 43:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44617/abstract/2\">",
"      Bacchetti P, Gripshover B, Grunfeld C, et al. Fat distribution in men with HIV infection. J Acquir Immune Defic Syndr 2005; 40:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44617/abstract/3\">",
"      Power R, Tate HL, McGill SM, Taylor C. A qualitative study of the psychosocial implications of lipodystrophy syndrome on HIV positive individuals. Sex Transm Infect 2003; 79:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44617/abstract/4\">",
"      Oette M, Juretzko P, Kroidl A, et al. Lipodystrophy syndrome and self-assessment of well-being and physical appearance in HIV-positive patients. AIDS Patient Care STDS 2002; 16:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44617/abstract/5\">",
"      Ammassari A, Antinori A, Cozzi-Lepri A, et al. Relationship between HAART adherence and adipose tissue alterations. J Acquir Immune Defic Syndr 2002; 31 Suppl 3:S140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44617/abstract/6\">",
"      Dub&eacute; MP, Parker RA, Tebas P, et al. Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides. AIDS 2005; 19:1807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44617/abstract/7\">",
"      Lichtenstein KA, Ward DJ, Moorman AC, et al. Clinical assessment of HIV-associated lipodystrophy in an ambulatory population. AIDS 2001; 15:1389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44617/abstract/8\">",
"      Joly V, Flandre P, Meiffredy V, et al. Increased risk of lipoatrophy under stavudine in HIV-1-infected patients: results of a substudy from a comparative trial. AIDS 2002; 16:2447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44617/abstract/9\">",
"      Mallal SA, John M, Moore CB, et al. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. AIDS 2000; 14:1309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44617/abstract/10\">",
"      Haubrich RH, Riddler SA, DiRienzo AG, et al. Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment. AIDS 2009; 23:1109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44617/abstract/11\">",
"      Fisac C, Fumero E, Crespo M, et al. Metabolic benefits 24 months after replacing a protease inhibitor with abacavir, efavirenz or nevirapine. AIDS 2005; 19:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44617/abstract/12\">",
"      Moyle G, Baldwin C, Mandalia S, et al. Changes in metabolic parameters and body shape after replacement of protease inhibitor With efavirenz in virologically controlled HIV-1-positive persons: single-arm observational cohort. J Acquir Immune Defic Syndr 2001; 28:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44617/abstract/13\">",
"      Mart&iacute;nez E, Conget I, Lozano L, et al. Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine. AIDS 1999; 13:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44617/abstract/14\">",
"      Mart&iacute;nez E, Garc&iacute;a-Viejo MA, Blanco JL, et al. Impact of switching from human immunodeficiency virus type 1 protease inhibitors to efavirenz in successfully treated adults with lipodystrophy. Clin Infect Dis 2000; 31:1266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44617/abstract/15\">",
"      Carr A, Workman C, Smith DE, et al. Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial. JAMA 2002; 288:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44617/abstract/16\">",
"      Martin A, Smith DE, Carr A, et al. Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study. AIDS 2004; 18:1029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44617/abstract/17\">",
"      McComsey GA, Ward DJ, Hessenthaler SM, et al. Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: the results of the TARHEEL study. Clin Infect Dis 2004; 38:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44617/abstract/18\">",
"      Moyle GJ, Sabin CA, Cartledge J, et al. A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy. AIDS 2006; 20:2043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44617/abstract/19\">",
"      Tien PC, Schneider MF, Cole SR, et al. Relation of stavudine discontinuation to anthropometric changes among HIV-infected women. J Acquir Immune Defic Syndr 2007; 44:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44617/abstract/20\">",
"      Grunfeld C, Saag M, Cofrancesco J Jr, et al. Regional adipose tissue measured by MRI over 5 years in HIV-infected and control participants indicates persistence of HIV-associated lipoatrophy. AIDS 2010; 24:1717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44617/abstract/21\">",
"      Opravil M, Hirschel B, Lazzarin A, et al. A randomized trial of simplified maintenance therapy with abacavir, lamivudine, and zidovudine in human immunodeficiency virus infection. J Infect Dis 2002; 185:1251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44617/abstract/22\">",
"      D:A:D Study Group, Sabin CA, Worm SW, et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet 2008; 371:1417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44617/abstract/23\">",
"      Strategies for Management of Anti-Retroviral Therapy/INSIGHT, DAD Study Groups. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS 2008; 22:F17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44617/abstract/24\">",
"      Tebas P, Zhang J, Yarasheski K, et al. Switching to a protease inhibitor-containing, nucleoside-sparing regimen (lopinavir/ritonavir plus efavirenz) increases limb fat but raises serum lipid levels: results of a prospective randomized trial (AIDS clinical trial group 5125s). J Acquir Immune Defic Syndr 2007; 45:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44617/abstract/25\">",
"      Moyle GJ, Andrade-Villanueva J, Girard PM, et al. A randomized comparative 96-week trial of boosted atazanavir versus continued boosted protease inhibitor in HIV-1 patients with abdominal adiposity. Antivir Ther 2012; 17:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44617/abstract/26\">",
"      Arioglu E, Duncan-Morin J, Sebring N, et al. Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes. Ann Intern Med 2000; 133:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44617/abstract/27\">",
"      Carr A, Workman C, Carey D, et al. No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial. Lancet 2004; 363:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44617/abstract/28\">",
"      Sutinen J, H&auml;kkinen AM, Westerbacka J, et al. Rosiglitazone in the treatment of HAART-associated lipodystrophy--a randomized double-blind placebo-controlled study. Antivir Ther 2003; 8:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44617/abstract/29\">",
"      Hadigan C, Yawetz S, Thomas A, et al. Metabolic effects of rosiglitazone in HIV lipodystrophy: a randomized, controlled trial. Ann Intern Med 2004; 140:786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44617/abstract/30\">",
"      Cavalcanti RB, Raboud J, Shen S, et al. A randomized, placebo-controlled trial of rosiglitazone for HIV-related lipoatrophy. J Infect Dis 2007; 195:1754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44617/abstract/31\">",
"      Mallon PW, Sedwell R, Rogers G, et al. Effect of rosiglitazone on peroxisome proliferator-activated receptor gamma gene expression in human adipose tissue is limited by antiretroviral drug-induced mitochondrial dysfunction. J Infect Dis 2008; 198:1794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44617/abstract/32\">",
"      Hadigan C. Peroxisome proliferator-activated receptor gamma agonists and the treatment of HIV-associated lipoatrophy: unraveling the molecular mechanism of their shortcomings. J Infect Dis 2008; 198:1729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44617/abstract/33\">",
"      Tungsiripat M, Bejjani DE, Rizk N, et al. Rosiglitazone improves lipoatrophy in patients receiving thymidine-sparing regimens. AIDS 2010; 24:1291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44617/abstract/34\">",
"      Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356:2457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44617/abstract/35\">",
"      Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 2009; 373:2125.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm226976.htm.  Accessed Nov 8, 2010. (Accessed on December 14, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44617/abstract/37\">",
"      Calmy A, Hirschel B, Hans D, et al. Glitazones in lipodystrophy syndrome induced by highly active antiretroviral therapy. AIDS 2003; 17:770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44617/abstract/38\">",
"      Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007; 298:1180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44617/abstract/39\">",
"      Slama L, Lanoy E, Valantin MA, et al. Effect of pioglitazone on HIV-1-related lipodystrophy: a randomized double-blind placebo-controlled trial (ANRS 113). Antivir Ther 2008; 13:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44617/abstract/40\">",
"      Colmers IN, Bowker SL, Majumdar SR, Johnson JA. Use of thiazolidinediones and the risk of bladder cancer among people with type 2 diabetes: a meta-analysis. CMAJ 2012; 184:E675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44617/abstract/41\">",
"      Grinspoon S. Use of thiazolidinediones in HIV-infected patients: what have we learned? J Infect Dis 2007; 195:1731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44617/abstract/42\">",
"      Walker UA, Auclair M, Lebrecht D, et al. Uridine abrogates the adverse effects of antiretroviral pyrimidine analogues on adipose cell functions. Antivir Ther 2006; 11:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44617/abstract/43\">",
"      Sutinen J, Walker UA, Sevastianova K, et al. Uridine supplementation for the treatment of antiretroviral therapy-associated lipoatrophy: a randomized, double-blind, placebo-controlled trial. Antivir Ther 2007; 12:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44617/abstract/44\">",
"      McComsey GA, Walker UA, Budhathoki CB, et al. Uridine supplementation in the treatment of HIV lipoatrophy: results of ACTG 5229. AIDS 2010; 24:2507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44617/abstract/45\">",
"      Lee JH, Chan JL, Sourlas E, et al. Recombinant methionyl human leptin therapy in replacement doses improves insulin resistance and metabolic profile in patients with lipoatrophy and metabolic syndrome induced by the highly active antiretroviral therapy. J Clin Endocrinol Metab 2006; 91:2605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44617/abstract/46\">",
"      Mulligan K, Khatami H, Schwarz JM, et al. The effects of recombinant human leptin on visceral fat, dyslipidemia, and insulin resistance in patients with human immunodeficiency virus-associated lipoatrophy and hypoleptinemia. J Clin Endocrinol Metab 2009; 94:1137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44617/abstract/47\">",
"      Guaraldi G, Fontdevila J, Christensen LH, et al. Surgical correction of HIV-associated facial lipoatrophy. AIDS 2011; 25:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44617/abstract/48\">",
"      Funk E, Bressler FJ, Brissett AE. Contemporary surgical management of HIV-associated facial lipoatrophy. Otolaryngol Head Neck Surg 2006; 134:1015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44617/abstract/49\">",
"      Loutfy MR, Raboud JM, Antoniou T, et al. Immediate versus delayed polyalkylimide gel injections to correct facial lipoatrophy in HIV-positive patients. AIDS 2007; 21:1147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44617/abstract/50\">",
"      Cofrancesco J Jr, Brown T, Martins CR. Management options for facial lipoatrophy. AIDS Read 2004; 14:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44617/abstract/51\">",
"      Sutinen J. Interventions for managing antiretroviral therapy-associated lipoatrophy. Curr Opin Infect Dis 2005; 18:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44617/abstract/52\">",
"      Nadarajah JT, Collins M, Raboud J, et al. Infectious complications of Bio-Alcamid filler used for HIV-related facial lipoatrophy. Clin Infect Dis 2012; 55:1568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44617/abstract/53\">",
"      Burgess CM, Quiroga RM. Assessment of the safety and efficacy of poly-L-lactic acid for the treatment of HIV-associated facial lipoatrophy. J Am Acad Dermatol 2005; 52:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44617/abstract/54\">",
"      Humble G, Mest D. Soft tissue augmentation using sculptra. Facial Plast Surg 2004; 20:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44617/abstract/55\">",
"      Valantin MA, Aubron-Olivier C, Ghosn J, et al. Polylactic acid implants (New-Fill) to correct facial lipoatrophy in HIV-infected patients: results of the open-label study VEGA. AIDS 2003; 17:2471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44617/abstract/56\">",
"      Carey DL, Baker D, Rogers GD, et al. A randomized, multicenter, open-label study of poly-L-lactic acid for HIV-1 facial lipoatrophy. J Acquir Immune Defic Syndr 2007; 46:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44617/abstract/57\">",
"      Levy RM, Redbord KP, Hanke CW. Treatment of HIV lipoatrophy and lipoatrophy of aging with poly-L-lactic acid: a prospective 3-year follow-up study. J Am Acad Dermatol 2008; 59:923.",
"     </a>",
"    </li>",
"    <li>",
"     Sculptra&reg; (injectable poly-L-lactic acid) product monograph, Berwyn, PA: Dermik Laboratories, 2004 (package insert). 2004.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44617/abstract/59\">",
"      Silvers SL, Eviatar JA, Echavez MI, Pappas AL. Prospective, open-label, 18-month trial of calcium hydroxylapatite (Radiesse) for facial soft-tissue augmentation in patients with human immunodeficiency virus-associated lipoatrophy: one-year durability. Plast Reconstr Surg 2006; 118:34S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44617/abstract/60\">",
"      Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004; 292:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44617/abstract/61\">",
"      Gallant JE, DeJesus E, Arribas JR, et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 2006; 354:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44617/abstract/62\">",
"      Roubenoff R, Weiss L, McDermott A, et al. A pilot study of exercise training to reduce trunk fat in adults with HIV-associated fat redistribution. AIDS 1999; 13:1373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44617/abstract/63\">",
"      Th&ouml;ni GJ, Fedou C, Brun JF, et al. Reduction of fat accumulation and lipid disorders by individualized light aerobic training in human immunodeficiency virus infected patients with lipodystrophy and/or dyslipidemia. Diabetes Metab 2002; 28:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44617/abstract/64\">",
"      Hadigan C, Meigs JB, Rabe J, et al. Increased PAI-1 and tPA antigen levels are reduced with metformin therapy in HIV-infected patients with fat redistribution and insulin resistance. J Clin Endocrinol Metab 2001; 86:939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44617/abstract/65\">",
"      Hadigan C, Corcoran C, Basgoz N, et al. Metformin in the treatment of HIV lipodystrophy syndrome: A randomized controlled trial. JAMA 2000; 284:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44617/abstract/66\">",
"      Driscoll SD, Meininger GE, Lareau MT, et al. Effects of exercise training and metformin on body composition and cardiovascular indices in HIV-infected patients. AIDS 2004; 18:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44617/abstract/67\">",
"      Kohli R, Shevitz A, Gorbach S, Wanke C. A randomized placebo-controlled trial of metformin for the treatment of HIV lipodystrophy. HIV Med 2007; 8:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44617/abstract/68\">",
"      Schambelan M, Mulligan K, Grunfeld C, et al. Recombinant human growth hormone in patients with HIV-associated wasting. A randomized, placebo-controlled trial. Serostim Study Group. Ann Intern Med 1996; 125:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44617/abstract/69\">",
"      Engelson ES, Glesby MJ, Mendez D, et al. Effect of recombinant human growth hormone in the treatment of visceral fat accumulation in HIV infection. J Acquir Immune Defic Syndr 2002; 30:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44617/abstract/70\">",
"      Lo JC, Mulligan K, Noor MA, et al. The effects of recombinant human growth hormone on body composition and glucose metabolism in HIV-infected patients with fat accumulation. J Clin Endocrinol Metab 2001; 86:3480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44617/abstract/71\">",
"      Lo JC, Mulligan K, Noor MA, et al. The effects of low-dose growth hormone in HIV-infected men with fat accumulation: a pilot study. Clin Infect Dis 2004; 39:732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44617/abstract/72\">",
"      Kotler DP, Muurahainen N, Grunfeld C, et al. Effects of growth hormone on abnormal visceral adipose tissue accumulation and dyslipidemia in HIV-infected patients. J Acquir Immune Defic Syndr 2004; 35:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44617/abstract/73\">",
"      Grunfeld C, Thompson M, Brown SJ, et al. Recombinant human growth hormone to treat HIV-associated adipose redistribution syndrome: 12 week induction and 24-week maintenance therapy. J Acquir Immune Defic Syndr 2007; 45:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44617/abstract/74\">",
"      Lo J, You SM, Canavan B, et al. Low-dose physiological growth hormone in patients with HIV and abdominal fat accumulation: a randomized controlled trial. JAMA 2008; 300:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44617/abstract/75\">",
"      Lo J, You SM, Liebau J, et al. Effects of low-dose growth hormone withdrawal in patients with HIV. JAMA 2010; 304:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44617/abstract/76\">",
"      Koutkia P, Canavan B, Breu J, et al. Growth hormone-releasing hormone in HIV-infected men with lipodystrophy: a randomized controlled trial. JAMA 2004; 292:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44617/abstract/77\">",
"      Falutz J, Allas S, Kotler D, et al. A placebo-controlled, dose-ranging study of a growth hormone releasing factor in HIV-infected patients with abdominal fat accumulation. AIDS 2005; 19:1279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44617/abstract/78\">",
"      Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med 2007; 357:2359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44617/abstract/79\">",
"      Falutz J, Allas S, Mamputu JC, et al. Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation. AIDS 2008; 22:1719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44617/abstract/80\">",
"      Falutz J, Potvin D, Mamputu JC, et al. Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension. J Acquir Immune Defic Syndr 2010; 53:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44617/abstract/81\">",
"      Falutz J, Mamputu JC, Potvin D, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. J Clin Endocrinol Metab 2010; 95:4291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44617/abstract/82\">",
"      Clayton PE, Banerjee I, Murray PG, Renehan AG. Growth hormone, the insulin-like growth factor axis, insulin and cancer risk. Nat Rev Endocrinol 2011; 7:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44617/abstract/83\">",
"      Renehan AG, Zwahlen M, Minder C, et al. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 2004; 363:1346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44617/abstract/84\">",
"      Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 2007; 370:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44617/abstract/85\">",
"      Piliero PJ, Hubbard M, King J, Faragon JJ. Use of ultrasonography-assisted liposuction for the treatment of human immunodeficiency virus-associated enlargement of the dorsocervical fat pad. Clin Infect Dis 2003; 37:1374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44617/abstract/86\">",
"      Connolly N, Manders E, Riddler S. Suction-assisted lipectomy for lipodystrophy. AIDS Res Hum Retroviruses 2004; 20:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44617/abstract/87\">",
"      Gervasoni C, Ridolfo AL, Rovati L, et al. Maintenance of breast size reduction after mastoplasty and switch to a protease inhibitor-sparing regimen in an HIV-positive woman with highly active antiretroviral therapy-associated massive breast enlargement. AIDS Patient Care STDS 2002; 16:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/36/44617/abstract/88\">",
"      Jemsek JG, Arathoon E, Arlotti M, et al. Body fat and other metabolic effects of atazanavir and efavirenz, each administered in combination with zidovudine plus lamivudine, in antiretroviral-naive HIV-infected patients. Clin Infect Dis 2006; 42:273.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3700 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-122.96.59.103-18C17D12B8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_36_44617=[""].join("\n");
var outline_f43_36_44617=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RATIONALE FOR TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      FAT ATROPHY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Switching antiretrovirals",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Thiazolidinediones",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Rosiglitazone",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Pioglitazone",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Summary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Uridine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Leptin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Surgical approaches",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6175174\">",
"      - Gel fillers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6175181\">",
"      - Autologous fat transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      FAT DEPOSITION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Exercise",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Metformin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Growth hormone and related drugs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Recombinant human growth hormone",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Recombinant human growth hormone releasing hormone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Thiazolidinediones",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Surgical approaches",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/3700\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3700|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?18/40/19083\" title=\"table 1\">",
"      Potential interventions of Lipo",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/18/3370?source=related_link\">",
"      Considerations prior to initiating antiretroviral therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/43/26298?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of HIV-associated lipodystrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/26/26024?source=related_link\">",
"      Injectable soft tissue fillers: Permanent agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/23/23930?source=related_link\">",
"      Injectable soft tissue fillers: Semipermanent agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/3/49?source=related_link\">",
"      Management of dyslipidemia and cardiovascular risk in the HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/7/3192?source=related_link\">",
"      Physiology of insulin-like growth factor I",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/50/21290?source=related_link\">",
"      Thiazolidinediones in the treatment of diabetes mellitus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f43_36_44618="RPGN Light High";
var content_f43_36_44618=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F68861%7ENEPH%2F76472%7ENEPH%2F63060%7ENEPH%2F57096%7ENEPH%2F78020&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F68861%7ENEPH%2F76472%7ENEPH%2F63060%7ENEPH%2F57096%7ENEPH%2F78020&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Light micrograph showing crescentic glomerulonephritis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 253px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    High-power light micrograph in crescentic glomerulonephritis. The hypercellular circumferential crescent (arrows) is compressing the glomerular tuft in the center of the glomerulus and closing the capillary lumens.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal glomerulus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 253px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Light micrograph of a normal glomerulus. There are only 1 or 2 cells per capillary tuft, the capillary lumens are open, the thickness of the glomerular capillary wall (long arrow) is similar to that of the tubular basement membranes (short arrow), and the mesangial cells and mesangial matrix are located in the central or stalk regions of the tuft (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut G Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Light micrograph showing crescentic glomerulonephritis II",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 259px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    High-power light micrograph showing an active hypercellular crescent containing fibrin, which has a bright red appearance (long arrow). Note that the severe inflammatory injury has led to fragmentation of the glomerular tuft (short arrow) and to creation of a rent in the capsule (double arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal glomerulus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 253px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Light micrograph of a normal glomerulus. There are only 1 or 2 cells per capillary tuft, the capillary lumens are open, the thickness of the glomerular capillary wall (long arrow) is similar to that of the tubular basement membranes (short arrow), and the mesangial cells and mesangial matrix are located in the central or stalk regions of the tuft (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut G Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Immunofluorescence microscopy showing linear IgG",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 395px; height: 256px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Immunofluorescence microscopy showing characteristic linear deposition of IgG in anti-GBM antibody disease.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Immunofluorescence microscopy showing fibrin deposition",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 253px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Immunofluorescence microscopy showing intense deposition (bright areas in the upper right portion of the glomerulus) of fibrin within a circumferential crescent surrounding the glomerular tuft in any form of crescentic or rapidly progressive glomerulonephritis, including that due to anti-GBM antibody disease.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Electron micrograph in crescentic glomerulonephritis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 394px; height: 251px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Electron micrograph in RPGN showing characteristic breaks in the glomerular basement membrane (GBM) (arrows). These rents allow fibrin and cellular elements to enter Bowman's space and initiate crescent formation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Electron micrograph of a normal glomerulus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 377px; height: 266px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Electron micrograph of a normal glomerular capillary loop showing the fenestrated endothelial cell (Endo), the glomerular basement membrane (GBM), and the epithelial cells with its interdigitating foot processes (arrow). The GBM is thin, and no electron dense deposits are present. Two normal platelets are seen in the capillary lumen.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_36_44618=[""].join("\n");
var outline_f43_36_44618=null;
var title_f43_36_44619="Resource use in children with liver or spleen injury";
var content_f43_36_44619=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F78428&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F78428&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Guidelines for resource utilization in children with isolated liver or spleen injury",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"4\">",
"        CT grade",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        I",
"       </td>",
"       <td class=\"subtitle2\">",
"        II",
"       </td>",
"       <td class=\"subtitle2\">",
"        III",
"       </td>",
"       <td class=\"subtitle2\">",
"        IV",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        ICU stay (d)",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hospital stay (d)",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Predischarge imaging",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        None",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Postdischarge imaging",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        None",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Activity restriction (wk)*",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        6",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CT: computed tomography; ICU: intensive care unit.",
"     <br>",
"      * Return to normal age-appropriate activity; return to competitive contact sports should be individualized.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Stylianos S. Evidence-based guidelines for resource utilization in children with isolated spleen or liver injury. J Pediatr Surg 2000; 35:164. Illustration used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_36_44619=[""].join("\n");
var outline_f43_36_44619=null;
var title_f43_36_44620="Preventing and managing smoking relapse";
var content_f43_36_44620=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F54759&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F54759&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Preventing and managing relapse in smokers",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Intervention",
"       </td>",
"       <td class=\"subtitle1\">",
"        Technique",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"5\">",
"        <strong>",
"         Relapse prevention",
"        </strong>",
"       </td>",
"       <td>",
"        Every ex-tobacco user undergoing relapse prevention should receive congratulations on any success and strong encouragement to remain abstinent. When encountering a recent quitter, use open-ended questions designed to initiate patient problemsolving (eg, How has stopping tobacco use helped you?).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        The clinician should encourage the patient's active discussion of the topics below:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        The benefits, including potential health benefits, that the patient may derive from cessation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Any success the patient has had in quitting (duration of abstinence, reduction in withdrawal, etc)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        The problems encountered or anticipated threats to maintaining abstinence (eg, depression, weight gain, alcohol, other tobacco users in the household)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Management of relapse",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"3\">",
"        Lack of support for cessation",
"       </td>",
"       <td>",
"        Schedule followup visits or telephone calls with the patient",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Help the patient identify sources of support within his or her environment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Refer the patient to an appropriate organization that offers cessation counseling or support",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Negative mood or depression",
"       </td>",
"       <td>",
"        If significant, provide counseling, prescribe appropriate medications, or refer the patient to a specialist",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Strong or prolonged withdrawal symptoms",
"       </td>",
"       <td>",
"        If the patient reports prolonged craving or other withdrawal symptoms, consider extending the use of an approved pharmacotherapy or adding/combining pharmacologic medication to reduce strong withdrawal symptoms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"5\">",
"        Weight gain",
"       </td>",
"       <td>",
"        Recommend starting or increasing physical activity; discourage strict dieting",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Reassure the patient that some weight gain after quitting is common and appears to be self-limiting",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Emphasize the importance of a healthy diet",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Maintain the patient on pharmacotherapy known to delay weight gain (eg, bupropion SR, nicotine-replacement pharmacotheripies, particularly nicotine gum)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Refer the patient to a specialist or program",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"4\">",
"        Flagging motivation/feeling deprived",
"       </td>",
"       <td>",
"        Reassure the patient that these feelings are common",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Recommend rewarding activities",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Probe to ensure that the patient is not engaged in periodic tobacco use",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Emphasize that beginning to smoke (even a puff) will increase urges and make quitting more difficult",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Fiore MC, Jaen C, Baker T, et al. Treating tobacco use and dependence: 2008 update. Clinical Practice Guideline. Rockville, MD: US Department of Health and Human Services. Public Health Service. 2008.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_36_44620=[""].join("\n");
var outline_f43_36_44620=null;
var title_f43_36_44621="Treatment of cutaneous lupus";
var content_f43_36_44621=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F78893&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F78893&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Algorithm for the initial management of discoid lupus and subacute cutaneous lupus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 242px; height: 333px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_36_44621=[""].join("\n");
var outline_f43_36_44621=null;
var title_f43_36_44622="Brachial fem artery";
var content_f43_36_44622=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F72344&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F72344&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Brachial and femoral artery recordings from an adult with coarctation of aorta",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 288px; height: 298px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Tracings of the pulse pressure of the brachial and femoral arteries demonstrate the delay in the peak systolic pressure of the femoral artery compared with the peak pulse pressure in the brachial artery.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Crawford MH. Inspection and palpation of venous and arterial pulses. In: Examination of the Heart. Part 2. American Heart Association; New York 1990. Reprinted with permission. Copyright &copy; 1990 American Heart Association, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_36_44622=[""].join("\n");
var outline_f43_36_44622=null;
var title_f43_36_44623="CT scan in PKD";
var content_f43_36_44623=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F76800&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F76800&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    CT scan showing polycystic kidney disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 362px; height: 252px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Abdominal CT scan in a patient with polycystic kidney disease shows extensive cysts in both kidneys; the cysts have almost completely replaced the renal parenchyma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jonathan Kruskal, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_36_44623=[""].join("\n");
var outline_f43_36_44623=null;
